



# DIGITAL ACCESS TO SCHOLARSHIP AT HARVARD

## Pricing and Reimbursement in U.S. Pharmaceutical Markets

The Harvard community has made this article openly available.  
[Please share](#) how this access benefits you. Your story matters.

<b>Citation</b>	Berndt, Ernst R., and Joseph P. Newhouse. 2010. Pricing and Reimbursement in U.S. Pharmaceutical Markets. HKS Faculty Research Working Paper Series RWP10-039, John F. Kennedy School of Government, Harvard University.
<b>Published Version</b>	<a href="http://web.hks.harvard.edu/publications/workingpapers/citation.aspx?PubId=7414">http://web.hks.harvard.edu/publications/workingpapers/citation.aspx?PubId=7414</a>
<b>Accessed</b>	February 18, 2015 9:50:09 PM EST
<b>Citable Link</b>	<a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:4450127">http://nrs.harvard.edu/urn-3:HUL.InstRepos:4450127</a>
<b>Terms of Use</b>	This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a>

*(Article begins on next page)*



**HARVARD Kennedy School**  
JOHN F. KENNEDY SCHOOL OF GOVERNMENT

# **Pricing and Reimbursement in U.S. Pharmaceutical Markets**

## Faculty Research Working Paper Series

---

**Ernst R. Berndt**

MIT Sloan School of Management and NBER

**Joseph P. Newhouse**

Harvard School of Public Health, Harvard Kennedy School,  
and NBER

**September 2010**  
**RWP10-039**

The views expressed in the **HKS Faculty Research Working Paper Series** are those of the author(s) and do not necessarily reflect those of the John F. Kennedy School of Government or of Harvard University. Faculty Research Working Papers have not undergone formal review and approval. Such papers are included in this series to elicit feedback and to encourage debate on important public policy challenges. Copyright belongs to the author(s). Papers may be downloaded for personal use only.

NBER WORKING PAPER SERIES

PRICING AND REIMBURSEMENT IN U.S. PHARMACEUTICAL MARKETS

Ernst R. Berndt  
Joseph P. Newhouse

Working Paper 16297  
<http://www.nber.org/papers/w16297>

NATIONAL BUREAU OF ECONOMIC RESEARCH  
1050 Massachusetts Avenue  
Cambridge, MA 02138  
August 2010

Revised version to appear in Patricia M. Danzon and Sean Nicholson, eds., *The Economics of the Biopharmaceutical Industry*. The authors have benefited from discussions with Richard G. Frank and E. Mick Kolassa, but are solely responsible for the views expressed herein. This research was not sponsored. The views expressed herein are those of the authors and do not necessarily reflect the views of the National Bureau of Economic Research.

© 2010 by Ernst R. Berndt and Joseph P. Newhouse. All rights reserved. Short sections of text, not to exceed two paragraphs, may be quoted without explicit permission provided that full credit, including © notice, is given to the source.

Pricing and Reimbursement in U.S. Pharmaceutical Markets  
Ernst R. Berndt and Joseph P. Newhouse  
NBER Working Paper No. 16297  
August 2010  
JEL No. D4,I11,I18,L11,L65

**ABSTRACT**

In this survey chapter on pricing and reimbursement in U.S. pharmaceutical markets, we first provide background information on important federal legislation, institutional details regarding distribution channel logistics, definitions of alternative price measures, related historical developments, and reasons why price discrimination is highly prevalent among branded pharmaceuticals. We then present a theoretical framework for the pricing of branded pharmaceuticals, without and then in the presence of prescription drug insurance, noting factors affecting the relative impacts of drug insurance on prices and on utilization. With this as background, we summarize major long-term trends in copayments and coinsurance rates for retail and mail order purchases, average percentage discounts off Average Whole Price paid by third party payers to pharmacy benefit managers as well as average dispensing fees, and generic penetration rates. We conclude with a summary of the evidence regarding the impact of the 2006 implementation of the Medicare Part D benefits on pharmaceutical prices and utilization, and comment on very recent developments concerning the entry of large retailers such as Wal-Mart into domains traditionally dominated by large retail chains and the "commoditization" of generic drugs.

Ernst R. Berndt  
MIT Sloan School of Management  
100 Main Street, E62-518  
Cambridge, MA 02142  
and NBER  
eberndt@mit.edu

Joseph P. Newhouse  
Division of Health Policy Research and Education  
Harvard University  
180 Longwood Avenue  
Boston, MA 02115-5899  
and NBER  
newhouse@hcp.med.harvard.edu

## **I. Introduction**

The pricing and reimbursement of prescription drugs in the United States is important for at least two reasons. First, from the perspective of US consumers, prescription drugs constitute 12 percent of total U.S. health care spending (2008) or roughly two percent of GDP.<sup>1</sup> Thirty-seven percent of this amount was tax financed, with the associated deadweight loss to finance that spending.<sup>2</sup> An additional 42 percent was financed through insurance, the bulk of which flowed through employer provided and subsidized insurance. The employer subsidies for this insurance cause distortions in the labor market with associated inefficiencies.<sup>3</sup> Thus, the financing of pharmaceuticals in the U.S. is associated with various types of deadweight losses. Second, from the perspective of all consumers, the U.S. constitutes about 40 percent of the world pharmaceutical market. As a result, its pricing and regulatory policies materially influence world demand and hence the incentives of pharmaceutical firms to innovate.<sup>4</sup>

In this survey chapter on pricing and reimbursement in U.S. pharmaceutical markets, we first provide background information on important federal legislation, institutional details regarding distribution channel logistics, definitions of alternative price measures, related historical developments, and reasons why price discrimination is highly prevalent among branded pharmaceuticals. We then present a theoretical framework for pricing of branded pharmaceuticals without and then in the presence of prescription drug insurance, noting factors affecting the relative impacts of insurance on prices and on utilization. With this as background, we summarize major long-term trends in copayments and coinsurance for retail and mail order purchases, average percentage discounts off Average Wholesale Price paid by third party payers to pharmacy benefit managers as well as average dispensing fees, and generic penetration rates. We conclude with a summary of the evidence regarding the impact of the 2006 implementation of the Medicare Part D benefits on pharmaceutical prices and utilization, and comment on very recent developments concerning the entry of large retailers such as Wal-Mart into domains traditionally dominated by large retail chains and the “commoditization” of generic drugs.

## **II. Background: Legislation, Institutions and Historical Developments**

We begin with a brief background section that focuses on important U.S. legislative developments. This lays the groundwork for our later discussion of the marketing and pricing of generic and brand prescription drugs in the U.S. For the most part the U.S. generic drug industry approximates competitive conditions with price approaching marginal costs. As a result, we employ traditional microeconomic tools to describe the structure and pricing of that industry. We defer discussion of brand pricing in the presence of market power to later in this chapter. Next we outline the structure and distribution logistics of U.S. markets for pharmaceuticals, distinguishing roles and prices faced by providers from those of payers. Then, since any researcher focusing on the pricing of branded and generic drugs in the U.S. cannot avoid encountering the critical functions played by the misnamed Average Wholesale Price (“AWP”, aka “Ain’t What’s Paid”), we digress to provide background on the origins, history and evolution of the very important and sometimes misunderstood central role played by AWP in various segments of the U.S. pharmaceutical industry. We conclude this section with a discussion highlighting the demand and cost conditions facing biopharmaceutical manufacturers that make third degree price discrimination an attractive and widespread practice.

### *A. Important Legislative Developments Affecting Drug Pricing*

The pricing of branded and generic drugs has long been a focus of controversy. Although Congressional attention to pharmaceutical pricing dates back further, a good place to begin is with the Congressional hearings conducted by Senator Estes Kefauver’s Anti-Trust and Monopoly subcommittee between 1959 and 1962. These hearings dealt not only with the thalidomide tragedy in which many children were born with birth defects as a result of their mothers taking thalidomide for morning sickness during pregnancy, but also with allegations of pharmaceutical companies engaging in various questionable practices to realize excess profits. One writer describes the hearings as follows:

“Witnesses told of conflicts of interest for the AMA (whose Journal, for example, received millions of dollars in drug advertising and was, therefore, reluctant to challenge claims made by drug company ads)...The drug companies themselves were shown to be engaged in frenzied advertising campaigns designed to sell trade name versions of drugs that could otherwise be prescribed under generic names at a fraction of the cost; this competition, in turn, had led to the marketing

of new drugs that were no improvements on drugs already on the market but, nevertheless, heralded as dramatic breakthroughs without proper concern for either effectiveness or safety.”<sup>5</sup>

Kefauver’s hearings led to enactment of the Kefauver-Harris Drug Act in 1962, also known as the Kefauver-Harris Amendments to the 1938 Food, Drug and Cosmetic Act. Among its numerous important provisions were that sponsors of New Drug Applications needed to document evidence of both safety and efficacy (not just safety), that informed consent was required of patients participating in clinical trials, that the sponsor file an Investigational New Drug application with the Food and Drug Administration before initiating human testing, that drug advertising be required to disclose accurate information about side effects, and provisions that stopped inexpensive to manufacture generic drugs from being marketed as expensive drugs under new trade names as new breakthrough medications, and that prevented the use of generic names that were obscure and difficult to remember, a practice that manufacturers allegedly employed to diminish generic substitution. It also mandated that a Drug Efficacy Study Implementation be undertaken to classify all pre-1962 drugs that already were on the market as either effective, ineffective, or needing further study.<sup>6</sup> For our purposes here, the Kefauver-Harris Drug Act Amendments of 1962 are notable for clarifying distinctions between brand and generic drugs and regulating their marketing.

Another important development of the 1960s was the 1965 passage of Congressional legislation adding Titles XVIII (Medicare) and XIX (Medicaid) as Amendments to the Social Security Act, which took effect in July 1966. At that time, however, Medicare covered only prescription drugs taken by hospital inpatients under Part A and physician administered drugs (typically injections) under Part B. Part D of Medicare which covered outpatient drugs taken orally -- small molecule drugs -- would not take effect until 40 years later in 2006.

Also in the mid 1960s drug wholesalers envisaged a potential growth in demand for generic drugs, and a number of them, such as McKesson vertically integrated into manufacturing operations and began marketing their own generics. Part of the wholesalers’ incentive to integrate into generic manufacturing and marketing arose because wholesaler margins were traditionally keyed to the price at which the

manufacturer suggested the wholesaler should sell, and to the extent generics were lower priced than brands, the prospect of manufacturers shifting their prescription drug mix toward generics implied a reduced gross profit margin for wholesalers. Contemporary industry analysts opined that the generic manufacturing and marketing window for wholesalers would, however, likely be a temporary one, as new specialized generic manufacturers entered the prescription drug market and marketed directly to the retail and hospital sectors.<sup>7</sup> We discuss changing dynamics in drug distribution channels, particularly the impacts of information and communication technologies, later on in this chapter.

A subsequent important legislative development was the Hatch-Waxman Drug Price Competition and Patent Term Restoration Act of 1984. It established the Abbreviated New Drug Application (“ANDA”) pathway that required only establishing bioequivalence with the reference drug (eliminating the need to establish safety and efficacy anew) and compliance with Good Manufacturing Practices.<sup>8</sup> It specified that when a generic manufacturer submitted an ANDA and successfully established bioequivalence with the originator drug and complied with Good Manufacturing Procedures, the Food and Drug Administration (“FDA”) was authorized to approve the ANDA. For oral solid small molecules, along with ANDA approval the FDA assigns the generic an A (therapeutically equivalent) or B (drug not considered therapeutically equivalent) rating with the pioneer, thereby enabling pharmacists to substitute a generic for the brand prescription.<sup>9</sup> It is worth noting that the FDA’s A rating essentially grants complete interchangeability between brand and generic, or what economists would call almost “perfect substitutability” of the brand and generic.<sup>10</sup> A weaker form of substitutability between different molecules occurs when, for example, payers (not necessarily the FDA) term two different molecules as being “therapeutically substitutable.”

### *B. Pricing of Generic Drugs*

As noted above, the traditional microeconomic theory toolkit is mostly sufficient for analyzing generic drug pricing. For the most part one can view generic drug manufacturers as operating in competitive markets, taking the price of generic drugs as given, and facing no buyer with monopsony power.



For most small molecule pharmaceuticals (i.e., most tablets or capsules), the process of undertaking clinical trials to establish bioequivalence and meet ANDA requirements is inexpensive relative to establishing efficacy; estimates range from \$2-5 million.<sup>11</sup> With entry being relatively inexpensive and the regulatory pathway open and clear, one would expect extensive generic entry following patent expiration, with price eventually falling to marginal cost. Indeed, that is what numerous researchers have found. Frank and Salkever [1997], Reiffen and Ward [2005], Atanu, Grabowski, Birnbaum, Greenberg and Bizan [2006], and Berndt, Mortimer, Bhattacharjya, Parece and Tuttle [2007] all find that price and the extent of generic entry are jointly determined. Reiffen and Ward also report that generic price continues to fall as the number of generic entrants increases up to five or so, but thereafter levels off. A common finding from the literature is that the number of generic entrants increases with the size of the branded molecule market (measured in dollars) prior to the loss of patent protection; generic entry of oral solids tends to be more extensive than that of injectables. Scott Morton [1997, 1999] considers various aspects of generic entry decisions in detail, and finds that generic firms tend to specialize in the therapeutic classes in which they have previous experience.

Three notable exceptions to envisaging the generic drug industry as being competitive with price approximating marginal cost are worth noting, each involving some aspect of market power. First, under the terms of the Hatch-Waxman Act, before or after submitting its ANDA, a generic manufacturer who successfully prevails in challenging the brand innovator’s patent claims can be granted 180 days of exclusivity during which time no other ANDA holder for that molecule/strength can market its product. This is typically called a Paragraph IV entry.

With no further ANDA entry permitted for a period of 180 days, the market for that particular molecule/strength becomes a duopoly, with the branded and single generic as competitors. In such a duopoly environment, the price of generics is generally only 10-20% below that of the brand.<sup>12</sup> A variant of this occurs when the branded manufacturer enters into an agreement with a generic manufacturer (other than the successful Paragraph IV entrant) to market the molecule/strength under the branded product’s original New Drug Application (not an ANDA). This has been dubbed “authorized generic entry”, and it enables the branded company to continue pricing its

branded product high after loss of patent protection, and rather than ceding all generic sales to the single successful Paragraph IV entrant, it can share generic revenues with its collaborating “authorized generic” entrant in a triopoly environment for up to 180 days.<sup>13</sup> Following the 180 day Paragraph IV exclusivity period, generic entry tends to be substantial, with generic prices falling sharply. The presence of authorized generic entry does not appear to adversely impact the extent of subsequent generic entry post-180 day exclusivity, although it might do so in cases where the size of the potential generic market is small.<sup>14</sup>

A second exception involves what is called “branded generics”. For example, a common feature observed in antidepressant markets in the 1980s following loss of patent protection was primarily branded manufacturers other than the original patent holder entering with similar strength (or with the off-patent molecule in combination with other molecules) therapeutic formulations but branded with other than the generic name.<sup>15</sup> Branded generics attempt to differentiate themselves from both the original branded patent holder and other generic entrants, and charge prices in between the generic and the original brand. While not particularly successful in the last few decades, branded generics may be rejuvenated in the context of biosimilars, as we discuss next.

A third potential exception to generic or patent expiration follow-on markets being approximated as competitive with price close to marginal cost involves biologics, as distinct from small molecules. Prior to 2010 there was no procedure for generic entry of biologics, now dubbed “biosimilars.” Section 7002 of the 2010 health care reform legislation (the Patient Protection and Affordable Care Act), however, established the authority for the licensure of biosimilars, which are intended to provide price competition for the original biologic; it granted the original biologic 12 years of market exclusivity.

The term biosimilar rather than generic drug is used not only because biologics are considerably larger and more complex molecules than are synthesized small molecules, and tend to be more challenging and costly to manufacture,<sup>16</sup> but also because their larger size and complexity implies possibilities of their surfaces folding in different ways, thereby not blocking receptor sites as uniformly as synthesized small molecules. Hence, characterizing them analytically and establishing bioequivalence between the original biologic and an attempted follow-on biologic entrant raises difficult scientific

issues and challenges with important economic implications. In particular, because of greater manufacturing costs and complexity, difficulties in establishing bioequivalence and meeting other regulatory requirements, it is widely anticipated that the extent of follow-on biologic entry subsequent to loss of patent protection will be considerably less than has historically been observed with chemically synthesized small molecules.<sup>17</sup> A consequence of this is that biosimilars are unlikely to experience the same degree of price competition following loss of patent protection as brands that A or B-rated bioequivalent small molecules have encountered in the US.<sup>18</sup> Instead, as the 2010 health care reform legislation is implemented, one will likely see competition from something akin to “branded generics,” products that are less than perfectly substitutable with the branded biologic pioneers, but nonetheless positioned to act as possible therapeutic equivalents. Hence, price declines of biologics following loss of patent protection are likely to be notably smaller than have occurred historically with generic small molecules.

### *C. Distribution Channel Logistics and Pricing*

Before initiating our discussion of the supply prices of branded drugs, we believe it useful to outline several logistical and transactional aspects of biopharmaceuticals, both generic and brand, including use of a variety of distribution channels. Observed prices of even the same biopharmaceutical will differ in various transactions simply because the drug pathway involves distinct distribution channel transactions.

It is important to distinguish consumers, providers and payers. We designate *providers* of pharmaceutical products as those entities that actually purchase and take both title and physical possession of biopharmaceutical products, either directly or indirectly providing them to consumers. Providers include retail and mail order pharmacies, various wholesalers, hospitals, and physician offices that administer medicines (typically by intravenous, infusion or injection). In comparison, *payers* such as health care plans, pharmaceutical benefit managers, most group purchasing organizations and employers, typically do not take title to and physical possession of drug products, but instead reimburse providers for the purchases they or their beneficiaries have made. Despite their name payers do not actually purchase drugs, and the prices involved in the transactions in which payers engage are not the purchase prices of drugs from manufacturers or wholesalers.

Brand manufacturers of small molecules sell their drugs primarily to certain providers, particularly wholesalers and chain warehouses, and have relatively limited direct sales to hospitals, retail and mail order pharmacies, and physician offices.<sup>19</sup> The price at which brand manufacturers sell to wholesalers and chain warehouses is generally the Wholesale Acquisition Cost (WAC), a published list price, minus a few percent discount for prompt payment and other incentives. In turn, wholesalers sell branded small molecules to retail and mail order pharmacies, usually at the present time at a few percent above their WAC, and at a 15-20% or larger discount off of what is known as the misleadingly named Average Wholesale Price (“AWP”).<sup>20</sup>

Wholesalers face different markets for branded and generic drugs. They can purchase branded drugs only from a single manufacturer, whereas they can purchase most generic drugs from many manufacturers. As a result, they can create price competition among the various generic manufacturers of a particular small molecule. Large retail chains also buy directly from generic manufacturers, pitting one generic manufacturer against others to obtain the lowest generic price. As a result, gross profit margins for both wholesalers and large retail chains are larger for generic than branded small molecules.<sup>21</sup>

In contrast, many biologics are administered via injection or infusion by health care providers (i.e., physicians and nurses), rather than being patient self-administered oral tablets or capsules purchased from retail or mail order pharmacies. As a result, manufacturers of branded biologics sometimes sell directly to hospitals and physician offices rather than to the wholesalers to which the branded small molecule manufacturers usually sell. Firms known as “specialty pharmaceuticals,” however, often provide wholesaler-type intermediary services between biologic manufacturers and providers. Although the practice is not as firmly ingrained as it is with branded small molecules, biologic manufacturers generally sell products to the specialty pharmaceutical firms at a slightly discounted WAC, and often at slightly higher prices to the providers who are buying directly.

Over the years a variety of intermediary services for all drugs have increasingly been provided by pharmaceutical benefit managers (“PBMs”). Services provided by PBMs include benefit design and contracting with manufacturers for third party payers

(insurers, employers, governments); pharmacy network formation; real time prescription benefit eligibility certification and claims processing; formulary management and rebate negotiations with manufacturers, payers and pharmacies; drug utilization screening and review; operation of mail order pharmacies, and other functions. Although PBMs are a critical component of the third party drug benefit system, in general they do not directly purchase prescription drugs from manufacturers, take title or physical possession of the product, or provide the drug product to the patient. Rather, they are best viewed as intermediary payers. If, however, the PBM owns a mail order pharmacy, as large PBMs do, then the PBM’s mail order pharmacy may perform provider services directly to patients.

Because of the multitude of agents involved in pharmaceutical transactions, a variety of *ex post* reconciliations and “true ups” occur. One of these is the *chargeback*. It arises because, as noted above, few brand manufacturers sell directly to providers, instead distributing their products primarily via wholesalers. Suppose that a manufacturer negotiates with a third party payer (“TPP”) or group purchasing organization (“GPO”), which does not take title to the product, a discounted price that is below the price the manufacturer charged the wholesaler. Pharmacies contracting with the TPP or members of the GPO purchase from the wholesaler at the contractually agreed on TPP/GPO price. The chargeback is the difference between the manufacturer’s price charged the wholesaler and the manufacturer’s contract price with the TPP/GPO and makes the wholesaler whole. Typically the wholesaler submits chargeback requests to the manufacturer on a regular basis, and the manufacturer transfers the invoiced chargeback to the wholesaler via electronic data interchange.

In addition to chargebacks, various forms of *rebates* are common in pharmaceutical transactions. Manufacturers contracting with TPPs/GPOs and PBMs often have market share or absolute number/dollar provisions that provide financial incentives for the TPPs/GPOs/PBMs to meet certain targets. e.g., a 10% of WAC rebate if brand x attains 40% of all dispensed prescriptions in a given, well-defined therapeutic class, and 15% if it attains 50%. Depending on the extent to which targets are attained or exceeded, manufacturers pay these organizations rebates. Since whether such target thresholds have been reached can typically only be determined retrospectively, these

rebates (or at least a portion of them) are paid *ex post* at regular intervals. PBM contracts with network pharmacies often contain similar rebate provisions, as do PBM contracts with TPPs.<sup>22</sup>

To this point we have not dealt with prices paid by consumers, be they completely cash paying uninsured or the much larger number of consumers whose insurance covers drugs. Regarding the latter, TPPs have attempted to constrain rising pharmaceutical expenditures by exerting financial pressures on the patient, altering cost-sharing provisions between the insurer and the insured consumer. Initially drug insurance involved the insured’s paying a copayment (a fixed dollar amount, usually for a month’s supply) or a coinsurance rate (a fixed percentage of the total cost) irrespective of the specific drug bought. Drug insurance also involved the insurer’s establishing a formulary, which was simply a list of drugs covered by the insurer. Formularies could be open or closed. Open formularies essentially cover all drugs approved by the FDA, whereas closed formularies cover only a subset of FDA approved drugs; for those drugs not covered, the insured must pay the full pharmacy price.

Drug benefit cost-sharing provisions have evolved over the last two decades, with the key innovation being to charge the customer different amounts for different drugs. When drug insurance was first introduced, the consumer typically paid the same coinsurance rate for any drug, but now the price paid by the customer depends on which “tier” the drug is placed. The first tiered plans typically had two tiers, but as we come to in Section IV, now there are usually three or even four. In such an arrangement, generic drugs will typically be on the lowest or cheapest (to the consumer) tier. When a customer brings a prescription for a generic drug on the first tier to the pharmacy, the customer pays the pharmacy a relatively small amount, say \$10 for a 30-day prescription. The TPP or its PBM pays the pharmacy the remaining cost of the drug and a dispensing fee. Relatively few benefit plans have many branded drugs on their first tiers, although occasionally a formulary will have an off-patent brand on the first tier.

Depending on the result of negotiations among the manufacturer and the PBM or TPP, for a given therapeutic class of drugs (e.g., anti-depressants) the insurer has one or more preferred brands on the second tier. A customer presenting a prescription to a

pharmacy for a branded drug on the second tier faces a larger copayment, say \$25 for a 30-day prescription, with the TPP or its PBM picking up the balance.

Brands for which the TPP or PBM was unable to negotiate a favorable price (from its perspective) are placed on the third tier. To incentivize customers and their physicians to substitute away from these non-preferred brands, copayments for third tier brands are considerably higher than for the second tier, say, \$50 for a 30-day prescription. Finally, certain very costly drugs, such as the oncology and rheumatoid arthritis biologics that can cost thousands of dollars per month, may be placed on a fourth tier. Even if the lower three tiers have increasingly higher copayments, the fourth tier, if the plan has four tiers, almost always has a coinsurance rate, perhaps 20-30%.

A relatively recent innovation involves prescriptions for maintenance drugs (drugs used to treat chronic rather than acute or episodic conditions). TPPs and PBMs now incentivize customers to obtain such drugs via mail order in 90 day prescriptions by making the copayments for 90 day prescriptions less than three times the 30 day copayment, often twice the 30 day copayment.<sup>23</sup> Another, even more recent innovation is to reduce cost sharing amounts for specific drugs (or specific classes of drugs) to encourage compliance and potentially reduce hospital and physician costs. We discuss this development below.

#### *D. The Long-Lived, Ubiquitous but Misnamed Average Wholesale Price*

In almost all brand drug transactions, reference is made to a “price” called the Average Wholesale Price (“AWP”). Although the role of AWP as a reference or benchmark price from which various discounts are taken is critical for contracting in these markets, the AWP is sometimes misunderstood, in part because it is neither an average nor a wholesale price.<sup>24</sup>

##### *D.1 The Creation and Evolution of Average Wholesale Price*

We now digress, initially to discuss the creation and evolution of the Average Wholesale Price (“AWP”) as a reference or benchmark for the pricing of numerous pharmaceutical transactions. Following Congressional passage of the federal Medicaid enabling legislation in 1965, the various states were required to develop beneficiary and reimbursement practices, subject to approval from the Health Care Financing Administration (“HCFA”, now the Centers for Medicare and Medicaid Services,

“CMS”). At that time, numerous small wholesalers existed, and while prices of prescription drugs were very low by current standards, they varied enormously. Large third party payers were coping with how to reimburse pharmacies for prescription pharmaceuticals they acquired and dispensed. Around the same time, in 1967 the United Auto Workers reached a precedent-setting agreement with Ford Motor Company enshrining drug insurance benefits as part of Ford employees’ benefit package. In both the private and public sectors, therefore, insurance covering prescription pharmaceuticals was becoming an increasingly important benefit. How would such drug insurance benefits be administered and claims processed efficiently among private and public payers, pharmacies and beneficiaries?

According to George Pennebaker [1998], early on California Medicaid program designers, who were conceiving a formula to facilitate reimbursement to pharmacies for costs incurred in dispensing prescription drugs to beneficiaries, focused on a total or aggregate reimbursement that consisted of a dispensing fee plus a reimbursement of acquisition costs. Regarding dispensing fees, under the leadership of Bill Apple, the American Pharmaceutical Association advocated a flat professional fee per dispensed prescription, independent of the pharmacy’s acquisition cost (thereby covering overhead costs and mitigating moral hazard issues to dispense ever costlier drugs, but not reimbursing pharmacies for inventory holding costs). Third party payers were sympathetic to this notion, as were pharmacy associations, but each struggled with how to determine pharmacy acquisition costs. For large payers, the number of invoice transactions was in the millions. Computers and information communication systems had not yet diffused widely. Third party public and private payers believed it was infeasible to check each pharmacy’s invoices, but allowing pharmacies simply to declare their costs to be whatever they decided would create perverse incentives. A standard or reference price was needed to facilitate pharmaceutical claims processing and reimbursement.

Officials at MediCal, California’s Medicaid prescription drug program, had helped in writing the federal Title XIX legislation.<sup>25</sup> Pennebaker, the first pharmacist hired by MediCal in November 1966, had to deal with reimbursing about 5,000 pharmacies who dispensed drugs to three million MediCal beneficiaries, at that time the largest third party drug benefit program in the nation. The major private sector program



with prescription drug benefits at the time was Blue Shield. Its reimbursement method required the pharmacy laboriously to fill out a four part carbon paper form, with the physician and pharmacy each keeping one copy, with two copies sent to Blue Shield. According to Pennebaker, after checking with several large wholesalers (Amerisource, Bergen Brunswick and McKesson), several independent wholesalers, and Blue Shield pharmacy analyst Bill Thompson, Pennebaker and his fellow MediCal pharmacist Vic Boisseree estimated informally, without any extensive mathematical calculations or precision, that pharmacies were “roughly on average with considerable variability” being reimbursed at the pharmacy’s acquisition cost plus a 35% markup and a \$1.00 - \$1.25 dispensing fee.<sup>26</sup> To facilitate California pharmacy buy in, Pennebaker and Boisseree decided to maintain or very slightly increase the total pharmacy reimbursement, but change the methodology so that the dispensing fee would be \$3.25. The \$2.00 - \$2.25 increase from \$1.00 - \$1.25 in the dispensing fee component corresponded with 35% of an actual pharmacy acquisition cost per prescription ranging between \$5.71 and \$6.43, which he thought was in the reasonable range of average pharmacy acquisition costs. Though he and Boisseree never explicitly defined AWP, Pennebaker named this “rough average” of actual pharmacy acquisition costs Average Wholesale Price, writing those words, in their first known usage, on his yellow paper pad.

As they traveled across California visiting pharmacies to explain the MediCal reimbursement policy of AWP plus \$3.25 dispensing fee, they were met with mixed reactions, although particularly sympathetic support emerged because of its conceptual and administrative simplicity. The major problem with implementing it was that at the time there was no list of AWPs for commonly dispensed prescription drugs, as AWP was not a term that was then being used in pharmaceutical transactions.

During the 1960s and 1970s and to some extent still today, pharmaceutical manufacturers differed in the extent to which they sold directly to pharmacies and other providers vs. indirectly via wholesalers and chain warehouses. When selling directly to providers, manufacturers also varied in the extent to which they provided information publicly on what prices manufacturers suggested retail pharmacies charge consumers. Drug Topics *Red Book* was one of several directory or catalog publications summarizing various drug prices; these catalogs served as a resource for pharmacists. Annual *Red*

*Book* catalog prices (supplemented twice yearly in January and May) provided information on “suggested selling price to consumer” and “cost price to the retail druggist”<sup>27</sup> at various drug strengths and package sizes. Prices paid by the retail druggist to acquire drugs were named “Trade List Prices”, and were separately identified as to whether the price referred to prices paid by the retailer on direct orders from the manufacturer, or by the retailer to the wholesaler.

Pennebaker’s wish for someone authoritatively to publish figures corresponding to his notion of AWP’s was soon fulfilled with the September 1969 publication of the 1970 annual edition of Drug Topics *Red Book*. The cover page of this *Red Book* highlighted a new product feature: “The only price directory in the drug field that shows Average Wholesale Prices and keeps up-to-date with supplements.”<sup>28</sup> Inside on the Product Information page, the 1970 *Red Book* explained (with some imprecision):

The price paid by the retailer to the wholesaler is either that suggested by the manufacturer or an independently determined Average Wholesale Price which is preceded by the symbol “(AWP)”. For the first time in the drug field the 1970 Drug Topics *Red Book* has procured and reports these Average Wholesale Prices for those drug products where the manufacturer has not suggested a price to be charged by wholesalers to indirect purchasing retailers. It has been independently obtained and calculated by the *Red Book*’s editorial staff from a representative group of wholesalers located in different areas throughout the country... There has been a long felt need for this type of price information and Drug Topics *Red Book* has gone to considerable effort to compile a meaningful price for its subscribers. It is hoped that the Average Wholesale Price may be used as a guide by wholesalers and retailers and the government agencies. Although this price is designed to show the average price retailers throughout the country are paying to the wholesaler for a particular item, it is not intended to be a standard or established price.<sup>29</sup>

The 1970 *Red Book* continued to distinguish a manufacturer’s price charged to direct customers from prices retailers paid to wholesalers, but beginning in 1970 added AWP figures, calling all of them “trade list prices”. Subsequent annual issues of the *Red Book* continued publication of the AWP, clearly designating it as a list price.<sup>30</sup>

Within months, a competitive price catalog publication, the American Druggist *Blue Book* 1970, also began publishing AWP, referring to it as a “trade list price” through 1975. In 1976, however, the *Blue Book* did away with the “trade list price” column heading and instead simply separately listed a new “Average Wholesale Price” and

“Direct Net Price”, stating in a footnote that the former was “Based on latest Blue Book surveys.” The Blue Book also added a new “Suggested Wholesale Price.”<sup>31</sup> The 1977 April update replaced the previous years’ footnote to Average Wholesale Price with an elongated dagger symbol referring to “Manufacturer’s Estimated AWP” prices.<sup>32</sup> A 1994 publication stated “BLUE BOOK AWP is either the published suggested wholesale price obtained from the manufacturer/labeler or the price commonly charged by wholesalers as determined by survey.”<sup>33</sup> Notably, George Pennebaker apparently never asked *Red Book* or *Blue Book* how they in fact obtained their estimates of AWP, stating simply that he thought the published AWP figures “looked reasonable”.<sup>34</sup>

#### *D.2 Relationships Between Branded AWP and Branded WAC*

Having discussed the creation and early evolution of the AWP notional price, we now turn to why it was that for most branded drugs in the 1970s and 1980s (and in many cases continuing on to this day), AWP tends to be 20% or 25% greater than WAC, implying that WAC is usually 16.7% or 20% smaller than AWP. The source of this relatively stable relationship for brands has been identified by Kolassa [1994]:

The AWP, the most common figure used for drug price comparisons, is a vestige of a drug distribution system that disappeared in the early 1980s. Prior to that time, there were several hundred small, independent drug wholesalers, each operating regionally. Due to the inefficiencies of such a fragmented system, the operating costs were quite high. The average markup above cost by these wholesalers to their retail customers, primarily pharmacies, was 20% to 25%, depending on manufacturer. The manufacturer differences were due to the fact that, while most pharmaceutical manufacturers used a wholesaler-only method of distribution to the retail class of trade, a significant number of large firms had invested in their own distribution networks and preferred ‘direct’ sales over the use of wholesalers. By convention, wholesalers added 20% to the price of products from companies following a wholesaler-only policy while adding 25% to the prices of products from those companies who chose to ‘compete’ with the wholesalers. At that time, virtually all pharmaceutical companies sold products directly to hospitals that did not use wholesalers. As a result, less than one-half of the pharmaceutical products sold in the United States were handled by drug wholesalers in the early 1970s.<sup>35</sup>

While Kolassa’s observations help explain sources of the 20% or 25% wholesaler markups to retailers, there is ample evidence that since the 1980s these wholesaler markups have declined substantially, with pharmacies acquiring branded drugs at discounts that approach 20% off of AWP, consistent with WAC plus a few percentage

points. This raises at least two issues: Why did the decline in wholesaler markups to retailers occur, and in the face of this trend, why has the ratio of AWP to WAC remained relatively stable for branded drugs? We first examine published trends in pharmacies’ ability to purchase branded prescription drugs at increasing discounts off AWP over time.

### *D.3 The Declining Markups of Drug Wholesaler Sales to Retailers*

Already in the late 1960s, evidence was accumulating that drug wholesaler margins were declining. Based on published data from the National Wholesale Druggists’ Association, Keller [1969] reports that wholesalers’ gross margins had fallen from 18% in 1950 to 15.3% of net sales in 1966, even as net profit before taxes fell from 4.1% to 2.9% of net sales; most of that margin decline occurred in the 1960s. The decline in drug wholesaler gross margins continued, however, falling to 14.4% in 1970 and then accelerated in the 1970s to 11.9% in 1977, the last year for which data are reported.<sup>36</sup>

The sustained decline in wholesaler gross margins reflects several offsetting trends. Fay [1980] documents the gradual increase over time in operating expenses until about the early 1960s, peaking at 14.0% of sales in 1961, then gradually declining to 12.3% in 1970, and falling more sharply in the 1970s, to 10.2% in 1977, the last year for which he reports data.<sup>37</sup> Part of the reason was the increasing cost during the 1950s of servicing geographically diffused pharmacies with an ever wider array of over-the-counter and prescription-only products. Beginning in the 1960s, however, the diffusion of information and communications technologies and the rationalization of product distribution logistics reduced operating costs. Throughout the 1957-77 time period, however, wholesaler discounts granted to pharmacy clients steadily increased – from 2.4% of net sales in 1957, 3.0% in 1963, 4.6% in 1967, 5.3% in 1970 and 6.5% in 1977.<sup>38</sup> Fay [1980, p. 37] quotes from the 1976 National Wholesale Druggists Association annual report, which stated “Almost every dollar gained in the operations area has been in turn dissipated through increased discounts.”

The increasing cost phenomenon during the 1950s actually favored large wholesalers over brand manufacturers, for branded drug manufacturers had much less scale and scope than did the large wholesalers, and as a result likely experienced even greater increasing costs in maintaining direct distribution to retailers. The increasing

costs of maintaining distribution networks with pharmacies not only created incentives for brand manufacturers to shed direct distribution with multiple regional warehouses and change to indirect sales networks via wholesalers with increasingly rationalized warehousing, but it also created incentives for consolidation among the wholesalers.<sup>39</sup> Consolidation during the 1960s and 1970s was likely driven in large part by computerization and the associated exploitation by wholesalers of economies of scale and scope. F.D.C. Reports [1966], publisher of a general pharmaceutical industry trade publication called *The Pink Sheet*, observed that a likely very powerful force changing the dynamics of wholesaling was the advent of electronic processing equipment that enabled wholesalers to improve the efficiency of their operations, exploit prospects for tying customers to a single wholesaler by offering to maintain continuing inventory records, provide pharmacies with software, and assist them in the installation of data phones tied to electronic equipment. Fay [1980, p. 42], cites in particular the role of automation of order entry processing:

“...the automation of the order entry process between retailer and wholesaler is clearly most important since it leads to all of the efficiencies and cost reduction inherent in the single source concept – a retailer concentrating nearly all of his orders with one supplier.”<sup>40</sup>

A related phenomenon affecting wholesale druggists was the emerging invasion of the retail trade more generally – not just the retail drug trade – by mass merchandisers and food chains. Recall that during the 1970s, following the pioneering practices of Sam Walton’s WalMart and other “superbox” retailers, widespread implementation of information and communications technological developments significantly impacted the rationalization of wholesaler-retailer or distribution center-retailer logistics, giving rise to new networks of automated distribution centers and “just in time” inventory management. Along with the increasing ability to monitor transactions in real time, thereby more efficiently managing inventory and product shipping, these developments exploited economies of both scale and scope, and in the process led to the demise of many small retail and wholesale firms. Kolassa [1994, pp. 236-7] describes how consolidating pharmaceutical wholesalers adopted more sophisticated inventory control systems and expanded software and communications hardware services to their client retail pharmacies and hospitals. Fay [1983] provides additional details on how computer

and information technology developments affected wholesaler-retail interactions in the pharmaceutical industry.<sup>41</sup>

With increasing consolidation among wholesalers, competition from mass merchandisers and food chains, and inexorable technological developments that facilitated exploitation of economies of scale and scope, thereby reducing product distribution and transaction monitoring costs, one would expect that prices charged retailers by wholesalers would have reflected increasing discounts off AWP. Note that if there is a relatively stable relationship of brand AWP list prices being 20% or 25% greater than brand WAC list prices, the actual discounts off AWP granted by wholesalers to retailers have an upper limit of about 20%; to the extent generic products have larger discrepancies between AWP and WAC, the average discount could be even greater. In fact, increasingly large discounts off AWP have been documented in a number of studies, both for brand and generic purchases by retailers from wholesalers.

Over the years, the Office of Inspector General (“OIG”) at the U.S. Department of Health and Human Services has conducted and publicly disclosed results of a number of investigations comparing Medicare and Medicaid reimbursement rates with commercial pharmacies’ and providers’ acquisition costs. For example, using 1994 invoice data sampled from Medicaid pharmacy providers in 11 states, the OIG found that pharmacies on average acquired branded drugs from wholesalers at an 18.3% discount off AWP.<sup>42</sup> Using 1995 data, a year when Medicare Part B physicians and suppliers were being reimbursed for branded and generic drugs at AWP - 5%, another OIG study concluded that for 22 drug codes representing Medicare’s largest Part B dollar outlays, the average discount over both brand and generic drugs was 29%.<sup>43</sup> A 2001 OIG study using 1997 Medicaid data from pharmacy invoices in eight states found that for these states, the average pharmacy acquisition cost for brands involved a 21.8% discount off AWP, an increase from the 19.3% observed in these states using 1994 data. OIG also compared WAC to actual acquisition prices for pharmacies, and determined that invoice prices were, on an average national basis, 1.8% below WAC.<sup>44</sup> Discounts off AWP list prices for generics were much larger, increasing on average from 55% off list using 1994 data to 65.9% based on 1997 invoice transactions.<sup>45</sup> Moreover, discounts off AWP were not confined to major government programs such as Medicare Part B and Medicaid, but also

occurred in the private sector. For example, referring to a 1993 report issued by the General Accounting Office, the Congressional Budget Office (“CBO”) in 1996 noted that private payers also received large discounts off AWP, stating “A recent General Accounting Office (GAO) survey found that four HMOs received an average discount off the published list price of 32 percent in 1990 and 34 percent in 1991 on their top 100 outpatient drugs.”<sup>46</sup>

Given that Medicare and Medicaid drug reimbursement rates to pharmacies used discounts off AWP that were much less than pharmacies were actually receiving, the declines in markups attained by wholesalers translated into increasing ingredient cost margins for pharmacies, particularly for generic drugs. In a 2004 CBO study that defined pharmacy markups as “the dollar difference between the total amount that Medicaid pays the pharmacy for each prescription and the amount that the pharmacy or wholesaler pays the manufacturer for the drug”<sup>47</sup>, the authors concluded that “Between 1997 and 2002, by CBO’s estimates, the average markup increased by nearly 60 percent – rising from \$8.70 to \$13.80 per prescription, or by about 9.7% per year.” CBO went on further, noting that:

Much of the increase in the average markup was attributable to the use of relatively new generic drugs. For generic drugs that came on the market between 1997 and 2002, Medicaid reimbursed pharmacies an average of about \$46 per prescription in 2002, of which only about \$14 went for the purchase of the drug itself. Pharmacies and wholesalers retained the remainder, or markup, of about \$32 per prescription.<sup>48</sup>

In summary, the combination of wholesaler consolidation and their exploitation of economies of scale and scope, facilitated by technological progress embodied in ever lower cost computers and information technology software and equipment, resulted in wholesaler markups and margins diminishing considerably over time, as actual pharmacy acquisition costs were increasingly discounted off the AWP list price.

The final issue we address in this lengthy digression on AWP pricing is why is it that branded manufacturers did not bring actual pharmacy acquisition costs closer to published AWPs. In other words, why have AWPs adhered to the 20% or 25% formulaic markup over WAC?

*D.4 Factors Locking in Branded Drugs’ AWP to WAC Relationships*

As the Drug Topics *Red Book* data description quoted above made clear, not all brand manufacturers provided data on the AWP of their drugs; others instead provided some form of alternative “suggested price.” In addition to surveying wholesalers and thereby generating their own estimates of AWP for data non-supplying manufacturers, price catalogs such as the *Red Book* and the *Blue Book* were able to generate AWP for manufacturers who previously had but no longer provided such data by examining whether historically the manufacturer had a 20% or 25% markup over WAC for its AWP or other “suggested price”, and continued to use that markup factor in generating their AWP.

Given the virtual universal presence of an AWP for drug products, whether supplied by the manufacturer or estimated by the price catalogs, transaction prices involving wholesalers, PBMs, pharmacies and other providers could all be specified with reference to AWP minus some x% discount. For example, a pharmacy could acquire all its brand drugs from the wholesaler at AWP – 18%, could be reimbursed by PBMs for dispensing any of its brand drugs at AWP – 13%, even as PBMs contracted with third party payers for all their brand drug costs at AWP – 10%. In this example, pharmacies’ gross margin would be 5% of AWP for all its brand drug sales, while the common margin for PBMs would be 3% of AWP.

The important point is that even though few if any transactions actually took place at the AWP price, the notional AWP served a valuable role as a common focal or reference point from which various discounts could be negotiated. While in theory pharmacies, PBMs and payers could negotiate separate AWP discounts that varied by manufacturer or drug, this would make electronic transactions more complicated and vulnerable to error. Rather, it was much simpler and more efficient for various contracts among PBMs, pharmacies and payers to specify the same percent off AWP for all branded drugs, regardless of manufacturer. Given AWP data entry into the networked computer system, very large numbers of various transactions among manufacturers, wholesalers, chain warehouses, retail and mail order pharmacies, other providers, PBMs and private and governmental payers could be processed and finalized expeditiously, efficiently and monitored very accurately. Hence, even though some observers



accurately called AWP “Ain’t What’s Paid,” AWP played a critical role in facilitating efficiently millions if not billions of transactions among the various manufacturers, providers, and payers<sup>49</sup>.

As wholesalers over time increasingly discounted off AWP in their sales to pharmacies and other providers, the “spread” between AWP and providers’ actual acquisition costs increased. For some providers, such as physicians providing Medicare Part B drug benefits (e.g., chemotherapy, other injected and infused therapies), the spread between AWP and the provider’s actual acquisition costs became an increasingly significant source of practice revenues. In the 1980s, for example, Medicare reimbursed these providers at full AWP, and in the early 1990s, at AWP – 5%. Any single manufacturer attempting to bring its AWP more in line with medical practice actual acquisition costs by unilaterally reducing its AWP and then discounting it less aggressively than its competitors would have been competitively disadvantaged, for as discussed above both Medicare and private contracts uniformly specified a common discount off AWP for all manufacturers.

To see this, consider the following. In the above Medicare Part B example, if in the 1990s a manufacturer decided unilaterally not to discount off AWP, all providers being reimbursed by Medicare Part B at AWP – 5% would lose 5% of AWP with every purchase; as AWP increased over time, the absolute amount of dollar losses incurred by the provider would increase. Each manufacturer unilaterally considering reducing AWP discounts to bring AWP closer to actual acquisition costs faced the same disincentive. In the language of economics and game theory, staying with the notional and in some sense “unrealistic” AWP system was a Nash equilibrium; it was competitively optimal for each manufacturer to adhere to the traditional WAC-to-AWP markup, given what other manufacturers (and the system of contracts) were doing. In short, individual manufacturers were locked into the AWP system, even if they wanted to change it.

An alternative possibility among brand manufacturers would involve their agreeing in a coordinated manner simultaneously to reduce their AWP so that it would be much closer to actual provider acquisition costs. In order to ensure that *relative* new AWP’s would be preserved across manufacturers from relative old AWP’s, thereby mitigating problems of gaming, the brand manufacturers would need also to agree to

reduce their new AWP by a common percentage from their old AWP. Moving AWP to more closely approximate providers’ actual acquisition costs would have required coordination.

One problem with such a coordinated mutual reduction in manufacturers’ AWP is that such actions would likely invite antitrust scrutiny and challenge from the U.S. Department of Justice. Notably, such antitrust concerns apparently occurred in the early 1990s when pharmaceutical manufacturers considered and then rejected the idea of mutually pledging to keep brand name drug prices from rising more rapidly than the Consumer Price Index, a proposal that the then Assistant U.S. Attorney General Anne Bingaman indicated

“...would violate the antitrust laws. An agreement among independent competitors that interferes with free and open price competition by restraining individual pricing decisions is a per se violation of the Sherman Act. The per se rule has been applied to agreements among competitors that fix or set the prices at which goods or services are sold as well as agreements that set price-related terms but not the specific price at which transactions occur.”<sup>50</sup>

Hence, such coordination among manufacturers attempting mutually to bring their AWP more in line with providers’ actual acquisition costs was infeasible since it was illegal.

Yet another possibility would be that major public sector purchasers, such as the Health Care Financing Administration (later renamed the Centers for Medicare and Medicaid Services, “CMS”) and the Veterans’ Administration could require that information on actual acquisition and/or manufacturers’ net revenues be made public, or at least be disclosed on a confidential basis to major public (and possibly private) sector payers. In fact, several variants of that possibility have emerged from legislation.

Specifically, when Congress passed the Omnibus Budget Reconciliation Act of 1990 (“OBRA 90”), it specified that the Medicaid programs receive a rebate that was the lower of a “best price” to a private purchaser, or 15.1% off the Average Manufacturer’s Price (“AMP”) for each drug, plus an allowance for inflation over and above that of the CPI. AMP was defined in federal law as the average price (including cash discounts and other price reductions) paid to drug manufacturers by U.S. wholesalers for drugs distributed to the retail class of trade. Retail here included mail order operations dispensing to patients. In turn, “best price” was defined in federal law as the lowest price

(including cash discounts and other price reductions) available from the manufacturer to any U.S. wholesaler, retailer, provider, health maintenance organization, nonprofit entity, or government entity, with some exceptions. In order to participate in Medicaid, manufacturers must report both AMPs and best prices. While CMS could audit manufacturers to ensure the accuracy of the manufacturer’s AMP and best price computations, the law required that CMS maintain the confidentiality of this AMP information, which therefore was not publicly available.<sup>51</sup>

In part because the various states’ Medicaid agencies were continuing to reimburse pharmacies at considerably smaller discounts off AWP than private payers were paying pharmacies, enabling pharmacies to retain the spread between their discounted AWP reimbursement and actual acquisition costs, in 2005 the Bipartisan Commission on Medicaid Reform recommended a change from AWP list prices to AMP actual prices, stating:

“There is widespread acceptance that AWP is inflated and does not reflect a valid benchmark for pricing. A different reference price should be established and made available to the states that more accurately reflects the actual price for drugs. The Average Manufacturer Price (AMP) should be used for this purpose.”<sup>52</sup>

For multiple source (generic) drugs dispensed to Medicaid recipients, the maximum amount a state Medicaid agency can reimburse a pharmacy is called the Federal Upper Limit (“FUL”).<sup>53</sup> Over the years the FUL has been computed based on a somewhat complex procedure involving AWP of generic drugs. States can choose to establish reimbursement limits below the FUL at a state maximum allowable cost (“MAC”). State-specific programs also establish dispensing fee and patient copayment policies, which have varied considerably among the states. As a general rule, the state-specific lists typically include more drugs, list newly available generic drugs more quickly, and establish more aggressive (i.e., lower) reimbursements than does the FUL list. Private payers also create their own MACs, whose construction details are typically proprietary.<sup>54</sup>

The Deficit Reduction Act of 2005 (“DRA”) mandated that CMS change the way in which FUL was determined for multiple source drugs using the formula AMP times 250%. AMP data was also to be published on the Internet. Final Rules for implementing

the AMP provisions were issued by CMS in July 2007. However, the National Association of Chain Drug Stores (“NACDS”) and the National Community Pharmacy Association (“NCPA”) successfully filed suit against CMS and in December 2007 won an injunction from U.S. District Court Judge Royce Lamberth that prevented CMS from adopting the AMP-based FUL determination and publishing AMP data on the Internet.<sup>55</sup>

The March 2010 health care reform legislation redefined AMP. Effective October 1, 2010, AMP is limited to sales to retail community pharmacies and wholesalers selling to these pharmacies (including independent, chain and supermarket pharmacies), but explicitly excluding mail order pharmacies, hospital pharmacies, and not-for-profit pharmacies. Since the excluded pharmacies have in the past been able to obtain substantially larger discounts than community pharmacies, the resulting AMP is larger than would be the case were these pharmacy transactions not excluded.<sup>56</sup> Rather than publishing prices at the individual manufacturer level for each drug, CMS is now required to post only the weighted average of the AMPs over multiple-source drugs, implying that pricing data for individual products will continue to remain confidential. The FUL applicable to each group of multiple source drugs is set at 175% of their weighted AMP. Ostensibly to mitigate significant quarter to quarter fluctuations, CMS is to apply a smoothing process. Notably the 2010 health care reform legislation also increased the Medicaid rebate for branded drugs from 15.1% to 23.1%.<sup>57</sup>

Turning from Medicaid to Medicare, under provisions of the Medicare Prescription Drug, Improvement and Modernization Act of 2003 (“MMA”), beginning January 1, 2005 Medicare Part B reimbursement for single-source (primarily on-patent originator brand drugs) became 106% of their two-quarter lagged average sales price (“ASP”) or their WAC, whichever is lower. The ASP is intended to represent the volume-weighted average manufacturer sales price net of rebates and discounts to all U.S. purchasers, excluding sales that are exempt from the Medicaid best price calculations and those to other federal purchasers. Rebates and discounts incorporated into the ASP calculation include volume discounts, prompt payment discounts, cash discounts, free goods that are contingent on any purchase requirement, chargebacks, and rebates to providers (not payers) other than those paid under the Medicaid rebate program. For new drugs and biologicals approved by the FDA, for the first two quarters

for which it is sold, the ASP is computed as 106% of WAC, or invoice pricing if the WAC is not published. Beginning in the third calendar quarter of its first year of U.S. sales, however, the ASP represents the average sales price lagged two quarters. Unlike AMP, however, ASP is posted by CMS on its website, and thus is publicly available.<sup>58</sup>

Yet another federal government purchase price is that on the Federal Supply Schedule (“FSS”) for pharmaceuticals, administered by the Veteran’s Administration (“VA”). It is a list of products and their prices available to federal entities that purchase prescription drugs. In order to have their products covered and paid for by Medicaid programs, under terms of OBRA 1990 and Veterans Health Care Act of 1992, manufacturers must agree to supply drugs at these prices. The FSS price is intended to equal or better the price that the manufacturer offers its most-favored nonfederal customer under comparable terms and conditions. Similar to the best price, to determine the Federal Ceiling Price (more on this below), manufacturers must provide the VA information on price discounts and rebates offered to domestic customers and the terms and conditions involved. The FSS price is publicly available.<sup>59</sup> The VA’s Office of Inspector General reviews the information used to determine the FSS price. Agencies using the FSS generally provide drugs directly to beneficiaries through their own pharmacies and facilities.<sup>60</sup> A related price is the Federal Ceiling Price (“FCP”) which is the maximum price manufacturers can charge for FSS-listed brand name drugs to the VA, Department of Defense, Public Health Service and the Coast Guard – even if the FSS price is higher. FCP must be at least 24% below the non-Federal AMP. Data on FCP prices are not publicly available.<sup>61</sup>

In summary, while the misnamed Average Wholesale Price remains and continues to play a critical role in providing a reference point for pharmaceutical transactions, for brands the discount off AWP has increased over time and likely will reach a peak as wholesaler markups over WAC decline to competitive levels. While manufacturers are locked in to the AWP system of pricing, the federal government has taken various steps to gain access to information that enables it to acquire or reimburse for branded pharmaceuticals at levels equal to or lower than paid by private purchasers. For generics, whether the federal government (and state Medicaid agencies) reimburse at levels equal to or lower than those paid by private purchasers is unclear, although historically that has

not been the case. Later on in this chapter we discuss other recent related developments involving payers’ attempts to make public pharmacy acquisition costs.

*D.5 The First DataBank - McKesson Settlement: Is AWP About To Die?*

To this point our discussion of AWP has emphasized that even though AWP is a reference price that increasingly diverged from actual pharmacy acquisition costs, remarkably it has endured and continued to play a critical role as a benchmark price for the multitude of transactions involving various private and public sector participants. However, developments of the last decade have led some industry observers to declare that the death of AWP, while not imminent, is inevitable.

On October 6, 2006, the *Wall Street Journal* published a front page article by Barbara Martinez reporting that First DataBank (“FDB”), the unit of Hearst Corporation publishing the *Blue Book*, in late 2001 had decided to increase the AWP to WAC markup from 1.20 to 1.25 for over 400 hundred drugs, in a secret agreement with drug wholesaler McKesson.<sup>62</sup> Third party payers and groups representing the uninsured sued FDB and McKesson. The Federal District Court Judge presiding over the ensuing litigation, Judge Patti B. Saris, described the FDB – McKesson conspiracy as follows:

“Typically, a drug’s wholesale acquisition cost or ‘WAC’ was understood as the price wholesalers paid to purchase a drug from the manufacturer; the WAC was then marked up by a fixed percent to derive the AWP. FDB represented that it surveyed wholesalers to ascertain the AWP, but this was untrue. Beginning in 2001, FDB and McKesson reached a secret agreement to raise the markup between WAC and AWP from its standard 20% to 25% for over four hundred drugs. McKesson communicated these new 25% WAC to AWP markups to FDB, which then published AWP’s with the new markup. To camouflage the scheme, McKesson and FDB agreed to effectuate price changes only when some other WAC-based price announcement was made by a drug manufacturer. McKesson has estimated that by 2002, 95% of all prescription drug manufacturers used the inflated 25% markup, and by 2004, 99% of all prescription drug manufacturers did so. The scheme ended on March 15, 2005, when FDB told its customers that it would ‘no longer survey drug wholesalers for information relating to AWP’. The scheme resulted in higher profits for retail pharmacies that purchase drugs on the basis of WAC but are reimbursed on the basis of AWP, a differential called the ‘spread’. McKesson implemented the scheme in order to provide a greater ‘spread’ to important retail pharmacy clients like Rite Aid as well as to its only pharmacy related businesses.”<sup>63</sup>

Any other stakeholder whose revenues (costs) depended on the spread, also profited (was adversely affected). Apparently both insurers (such as United Health) and manufacturers

contacted FDB asking for explanations of the AWP increase, but were unable to obtain a satisfactory explanation.<sup>64</sup>

In a January 2005 deposition, Kay Morgan, who had been in charge of AWP at FDB, testified that rather than FDB relying on surveys from various wholesalers, since late 2003 the only wholesaler providing FDB with markup information was McKesson.<sup>65</sup>

Without admitting to any wrongdoing, eventually both FDB and McKesson settled, although FDB’s initial 2006 and 2008 proposed settlements with plaintiffs were opposed by pharmacies and some PBMs;<sup>66</sup> McKesson agreed to a settlement in November 2008 just before the scheduled beginning of a trial. A final FDB settlement was not approved by the Court until March 2009. This final settlement was challenged by several organizations representing pharmacies, and an organization representing PBMs, but was upheld by the United States Court of Appeals for the First Circuit on September 3, 2009. Under terms of the settlements, McKesson agreed to pay \$350 million, and set aside a \$143 million reserve for certain future claims.<sup>67</sup> FDB issued a statement saying not only had it agreed to roll back the prices of approximately 1400 drugs identified in the plaintiffs’ previously filed complaint to a Blue Book AWP of 1.20 times the WAC or Direct Price effective September 26, 2009, but that independent of the settlement, by the same date, FDB would apply the identical 1.20 markup factor to all other drugs

“...whose Blue Book AWP is set based upon a markup to WAC or Direct Price in excess of 1.20. First DataBank will also independently discontinue publishing the Blue Book AWP data field for all drugs no later than two years following the date that the Blue Book AWP adjustments noted above are implemented.”<sup>68</sup>

FDB stated that it would, however, continue to publish other drug pricing information such as WAC, Direct Price, Suggested Wholesale Price, and Federal Upper Limits.

Interestingly, a year earlier, on January 23, 2008, Judge Saris issued an order denying approval of a previously proposed settlement which would have *required* that First DataBank cease publishing AWP within two years after the Court’s approval of the settlement, as long as no competitor continued publishing similar AWP data. Since AWP is so widely used by the various stakeholders involved in pharmaceutical transactions, the Court was concerned that the original settlement had the potential to affect many providers that were not parties in the lawsuit.<sup>69</sup> What would be the consequences of this

settlement for pharmacies and PBMs (not parties in the law suit), and would this create havoc in the entire pharmaceutical reimbursement system, undermining AWP? Who would be the winners and losers from this rollback, and would AWP itself survive as a benchmark price from which various discounts were negotiated?

In an affidavit an expert economist hired by plaintiffs estimated that the settlement would represent a reduction in costs of \$4.2 billion annually, of which \$3.8 billion was the impact on third party payers and pharmacies, and \$400 million on the uninsured. Plaintiffs worried that pharmacies would be seriously harmed by the rollback, unless public and private contract provisions were adjusted to offset the lower reimbursement.<sup>70</sup> A spokesman for the National Community Pharmacists Association stated that the settlement “will force many mom-and-pops out of business or make drastic service reductions, which would hurt consumers, especially in under-served low income or rural areas where chains are few”.<sup>71</sup> Benefits consulting firms were less alarmed, arguing that the pharmacy supply chain had already absorbed the AWP increases through a steady increase in the AWP discounts offered to payers and distributors, and expected that PBMs would approach their clients either to request or mandate that currently contracted discount guarantees be adjusted downward to make up for the rollback. Over the longer term, however, they voiced concerns that “FDB’s agreement to cease publication of the AWP created the very real possibility that AWP would be phased out completely as a pricing index.”<sup>72</sup>

As the September 26, 2009 AWP-to-WAC markup rollback date approached, observers predicted it would have little effect, since PBMs and others “adjusted their contracts so that PBMs, their clients and pharmacies will feel little or no financial pain.” PBMs described the rollback as “little more than an administrative headache”, saying that they and their clients had devised revenue neutral arrangements. Adam Fein, President of Pembroke Consulting, was quoted as saying “My view is that there’s not going to be much of a difference after Sept. 26...As I see it, the net impact on total U.S. drug spending will be relatively small and certainly far below the initial multibillion-dollar predictions from a few years ago.” However, one set of “winners” from the rollback were state Medicaid agencies, which for the most part had not renegotiated contracts with



pharmacies, and thus ended up paying pharmacies less, which by one estimated totaled \$550 million in just one year.<sup>73</sup>

While some observers suggested that WAC should eventually replace AWP as the benchmark price, others have noted that for brands the relationship between WAC and AWP is very stable, and since WAC is a list rather than transactions price, “Judge Saris’ critique of AWP could potentially be leveled against WAC, too.”<sup>74</sup> A 2010 collaboration among state Medicaid Directors resulted in the publication of a list of desired characteristics of a replacement for AWP, but was unable to reach a consensus regarding details.<sup>75</sup> On June 21, 2010, Wolters Kluwer Health, publisher of MediSpan which had previously acquired the Red Book pricing compendium, announced that it was temporarily reversing its May 2007 decision to discontinue publication of AWP by late 2011, since “no comprehensive alternative benchmark price is yet available.” In their pricing policy update press release, they stated:

“As a result, Wolters Kluwer Health intends to publish AWP (or a similarly determined benchmark price) until relevant industry or governmental organizations develop a viable, generally accepted alternative price benchmark to replace AWP. Wolters Kluwer Health expects to continue to support industry efforts to identify a widely accepted, alternative benchmark and, once such a viable AWP alternative exists, to work with customers to migrate the publication of that new price benchmark in place of AWP, under an appropriate implementation and transition schedule.”<sup>76</sup>

We return to the issue of how reimbursement models based on actual pricing data might ultimately become the dominant benchmark for pharmacy reimbursement later in this chapter, but now move on to a different aspect of pricing, namely, price discrimination.

#### *E. Price Discrimination in Prescription Pharmaceuticals*

In the previous pages we have spent considerable time discussing the various prices at which a multitude of transactions occur at differing points in the pharmaceutical distribution chain, and the roles of discounts, chargebacks and rebates. But even at the same point in the distribution chain, it is not uncommon for differing buyers to pay distinct prices for the identical drug; the practice of charging different prices for the identical product to distinct buyers is called price discrimination.<sup>77</sup> Economic theory suggests that for a firm to find the practice of price discrimination to be profitable and

sustainable, three factors must generally be present: (i) buyers must have heterogeneous marginal evaluations; (ii) firms must have market power; and (iii) arbitrage must be minimal, because it is costly and/or illegal.

Regarding buyers’ heterogeneous evaluations, a great deal of variability exists in the valuations patients place on drugs. Patients vary in their medical and functional responsiveness to a medication, and in the values they attach to different characteristics and effects of a drug (e.g., its side effect profile, dosing convenience, ability to keep functioning while at work or carry out activities of daily living when retired, or about a particular drug interaction). In considering a drug relative to other drug and non-drug therapies, the costs of physician office visits (including time and convenience aspects) and hospitalizations are also relevant.<sup>78</sup> There is likely also substantial diversity in patients’ willingness to pay for and/or exert efforts to attain or maintain certain health states. On the demand side, therefore, it is reasonable to expect that there is enormous heterogeneity in the marginal valuations of medications. This patient heterogeneity is a necessary condition for manufacturers to be able to practice price discrimination.

Second, firms must have market power. If a firm attempted to practice price discrimination in a perfectly competitive environment, it would either capture the entire market by pricing below marginal cost or find itself with excess inventory because buyers were purchasing from other sellers offering the product at lower cost. In the case of pharmaceuticals, firms can possess market power by virtue of their having a valid patent on the product, by the FDA granting the firm market exclusivity on that product for some other reasons (e.g., data exclusivity, pediatric extension, Orphan Drug status), or because of some other barriers to entry (e.g., manufacturing know-how, access to rare or limited raw materials). Possession of market power is yet another necessary condition for manufacturers to be able to practice price discrimination on a sustained basis.

Third, arbitrage must be minimal, because it is costly and/or illegal. If arbitrage were perfectly legal and costless, purchasers could buy at low cost from the manufacturer and resell to others willing to pay a higher price, thereby undoing and subverting the manufacturer’s attempted non-uniform pricing. For example, if a hospital were able to purchase a drug at a highly discounted price for inpatient use, it might wish to operate a retail pharmacy open to the public at which it could charge a much higher price.

In the U.S., the potential for arbitraging transactions is very limited, because of legislation making many such transactions illegal. The Prescription Drug Marketing Act of 1987, which became effective on July 21, 1988, was intended to reduce public health risks from adulterated, misbranded and counterfeit drug products that enter the marketplace through drug diversion.<sup>79</sup> The law provides that prescription drugs manufactured in the U.S. and exported can no longer be reimported, except by the product’s manufacturer. It also places restrictions on sales of prescription drugs and samples. Hospitals cannot sell prescription drugs to the general public.<sup>80</sup> Wholesale distributors must be licensed by the state and meet uniform standards. The practice of wholesalers reselling to each other, particularly drugs whose shelf life is about to expire, continues to be a focus of FDA regulatory attention.

Over the years since 1987, there has also been considerable Congressional attention and legislation regarding the reimportation of drugs for personal use, particularly from Canada. Currently implementation of such reimportation is under the discretionary authority of the FDA.<sup>81</sup>

For our purposes, it is sufficient to note that along with heterogeneity of consumers’ evaluations and the presence of manufacturer market power, arbitrage of prescription drugs in the U.S. is costly and in many cases illegal, and is insufficient to discourage the practice of price discrimination. Together these three conditions make sustained price discrimination of prescription drugs feasible.<sup>82</sup>

One other factor, this on the cost rather than demand side, makes price discrimination of prescription pharmaceuticals very attractive, and that is the high fixed/sunk cost, low marginal cost structure. A number of studies have estimated the costs of bringing a prescription pharmaceutical to market;<sup>83</sup> also see the chapters in this volume by DiMasi, “Costs and Returns to R&D”, and by Metrick and Nicholson, “Financing R&D”. The costs include opportunity costs of funds and failed projects. The most recent of these (DiMasi, Hansen and Grabowski [2003]) estimates that around the turn of the century, it took on average about \$802 million of 2000 dollars and 12 years to bring a new drug to market, including prepatent application R&D. The \$802 million is more than twice the \$350 million estimated a decade earlier, and in large part reflects increased costs of clinical development rather than basic R&D. Estimates in the same

general range have been reported by Adams and Van Brantner [2006]. However, while there appears to be substantial heterogeneity in development costs across therapeutic areas,<sup>84</sup> it appears that on average the costs of bring traditional chemically synthesized small molecule pharmaceuticals are about the same as that for large molecule biologics.<sup>85</sup>

In contrast to the fixed or sunk R&D costs, the variable and marginal costs of manufacturing and marketing a prescription pharmaceutical once it has been approved by the FDA are often very small, nickels and dimes, not dollars, for many small molecule pharmaceuticals; evidence on this is provided by the fact that following loss of patent protection and extensive generic entry, prices of generic drugs fall to as low as 10% of the brand price.<sup>86</sup> For some drugs, however, particularly large molecule proteins and biologics, manufacturing marginal costs can be substantial. Whether small molecule or biologic, therefore, relative to the fixed or sunk R&D costs, marginal production costs are much smaller, implying that returns to scale are substantial, and that as long as price compensates for marginal production and marketing costs, it will be profitable for the manufacturer to price discriminate.<sup>87</sup> Combined with the fact that three necessary conditions for price discrimination to be feasible and sustainable are met for pharmaceuticals – patient marginal evaluation heterogeneity, manufacturer market power and minimal possibilities to arbitrage – the presence of very substantial production scale economies implies that branded manufacturers face strong incentives to practice price discrimination.

Within the U.S., considerable price variability occurs across distribution channels, with the VA and Medicaid able to obtain very low brand prices, staff model health maintenance organizations slightly higher but still relatively low prices, third party payers higher prices depending in large part on their ability to implement tiered formularies, and retail pharmacies frequently paying the highest brand prices.<sup>88</sup> These practices gave rise to considerable litigation within the U.S. in the 1990s, with some economists arguing that since a necessary condition for third degree price discrimination to increase welfare (total quantity sold in all markets being greater than if a uniform price occurred across all markets<sup>89</sup>) likely was satisfied in the case of pharmaceuticals, such price discrimination was welfare enhancing within the U.S.<sup>90</sup> Others, however, argued that the practice of price discrimination unfairly affected pharmacies, particularly independent pharmacies.<sup>91</sup>

What is clear and relatively uncontested, however, is that third degree price discrimination is a common occurrence in the U.S. branded prescription drug industry.

A more enduring and perhaps even more passionate debate involves price discrimination across countries. Although for many years global brand pharmaceutical companies charged lower prices to southern European countries than to those in northern Europe and Great Britain, in the 1980s arbitrage (known as parallel importing) became more prevalent. The European Union has explicitly permitted parallel importing, and this has affected global branded pharmaceutical companies’ pricing strategies; for discussion, see Kyle [2007, 2009, 2010]. Danzon and Towse [2003] argue that the case for third degree price discrimination improving global economic welfare is much more complicated in the context of fixed and sunk R&D costs than it is for constant cost industries, and that instead the Ramsey pricing analysis of second-best pricing provides a more appropriate theoretical framework. Moreover, if (absolute values of) countries’ price elasticities of demand are positively related to countries’ income (per capita) levels, then not only might there be a strong case for third degree price discrimination on economic efficiency criteria, but it could also be consistent with standard norms of equity. Access pricing for pharmaceuticals via third degree price discrimination remains a controversial global policy issue. For further discussion, see the chapters in this volume by Patricia Danzon, “Pricing and Reimbursement: Other Countries”, and by Hannah Kettler, David Ridley and Adrian Towse, “Drugs for Developing Countries”.

Our goal in this introductory section on the economics of pharmaceutical pricing has been to provide an institutional background and introduction of various pricing concepts for the U.S. Having reviewed important U.S. legislation, characterized the generic industry as approximating a competitive market with price equal to marginal cost, outlined various distribution channel transactions along with their prices, discounts, chargebacks and rebates, digressed to summarize the creation and evolution of the misnamed but ubiquitous average wholesale price, and then discussed why the demand and cost conditions facing biopharmaceutical firms provide strong incentives for firms to practice intra- and inter-country third degree price discrimination, we now turn to a discussion of the economic theory foundations of supply prices for branded drugs.

### III. Supply Prices and Brand Name Drugs

#### A. Monopolist Prices With and Without Prescription Drug Insurance

Relative to most other developed country markets for pharmaceuticals, pricing in the U.S. pharmaceutical market more closely resembles pricing in standard (non-drug) economic markets (see also the Danzon chapter, “Pricing and Reimbursement: Other Countries”). Applying standard microeconomic tools to analyze these markets is therefore reasonably straightforward, although issues concerning asymmetric information, moral hazard, patient heterogeneity and physician agency preclude one from viewing market demand curves as reflecting the outcome of representative consumers maximizing utility subject to budget constraints. Here we simply assume the existence of downward sloping demand curves, but do not attempt to derive them based on consumer optimization theory.<sup>92</sup>

We begin by considering the simple - but in practice unusual - case of an on-patent drug with no close substitutes that is not covered by health insurance.<sup>93</sup> Viagra may be as close to an actual example as we can come. The elementary textbook model of monopoly pricing applies straightforwardly to this case; the profit maximizing price for the manufacturer will be at the quantity where marginal revenue and marginal cost are equal.

Specifically, if the inverse demand equation is linear and of the form

$$p = a - bq, \text{ where } a, b > 0, \quad (1)$$

p is price, q is quantity, and if total costs are

$$TC = c + dq, \text{ where } c, d > 0, \quad (2)$$

then the usual profit maximizing behavior yields optimal price  $p^*$  and quantity  $q^*$  as

$$p^* = (a + d)/2 \quad \text{and} \quad q^* = (a-d)/2b. \quad (3)$$

Notice that  $p^*$  does not depend on b, the slope of the demand curve;  $p^*$  is simply half the vertical distance between the constant marginal cost d and the market’s reservation price a. See Figure 1.

As time passes, therapeutic substitutes are likely to come on to the market for the drug that had no close substitutes when it was introduced, as has been the case with Viagra. As this happens standard models of differentiated monopoly or monopolistic




Figure 1

The inverse demand curve BC, corresponding to no insurance, has slope  $-b$ . The demand curve AC, corresponding to a coinsurance rate of 0.2, has slope  $= -5$ . Marginal revenue curves are the dotted lines corresponding to the two demand curves. Price at a coinsurance rate of 0.2 is not quite five times as great as with no insurance ( $i=1$ ).

competition apply. Prices will fall toward competitive levels, with each product retaining some market power to maintain price above competitive marginal cost levels.

Whether or not therapeutic substitutes have appeared, at some point the original drug will go off patent and generic competitors will enter. As more generic firms enter, the generic price falls to competitive levels. The original manufacturer may, however, produce a branded generic (e.g., Advil vs. the generic ibuprofen), which will command a price premium above generic or private labels.

This no insurance case, however, is exceptional, since approximately 85 percent of Americans have insurance coverage, and most of those policies cover drugs. Medicare beneficiaries use about three times as many drugs as the under 65, and around 90 percent of them have coverage for drugs.<sup>94</sup> Thus, we next consider how the standard model needs to be modified for the case of an insured consumer.

The simplest case to analyze is an insurance policy with a constant coinsurance rate  $i$  ( $0 < i \leq 1$ ), meaning the patient pays  $100i$  percent of the cost; for mathematical convenience, we rule out the completely free case ( $i = 0$ ). Policies with non-zero coinsurance rates were relatively common when health insurance began to cover prescription drugs in the 1970s and 1980s.<sup>95</sup> They are much less common today, but still are found, e.g., Medicare coverage of drugs taken orally for persons who spend above a certain (large) amount out-of-pocket face a 5 percent coinsurance rate.<sup>96</sup> A 20 percent coinsurance rate applies currently in Medicare for drugs injected during an office visit. Although many beneficiaries have a supplementary insurance policy that covers the 20 percent coinsurance amount, not all do.

We again begin with a drug with no close substitutes that is covered by such an insurance policy. Examples would be Mevacor (lovastatin), which in 1987 became the first statin on the U.S. market, and Gleevec (imatinib), which was launched in 2001 and still (in 2010) has no close substitutes for the treatment of chronic myelogenous leukemia. How one specifies the resulting with insurance inverse demand curve is somewhat speculative, since modeling precisely how both insurers and insureds would respond to the sudden possibility of insurance raises challenging issues. Let  $I^{-1} = 1/i$  (note we have excluded the  $i=0$  possibility). One possibility is to specify the new market demand equation with capital (rather than lower case) letters as



$$P = \Gamma^1(a - bQ) = A - BQ, \text{ where } A = \Gamma^1 a \text{ and } B = \Gamma^1 b. \quad (4)$$

Relative to the no insurance case, this with-insurance demand curve simply rotates clockwise and upward at the quantity demanded when the price equals zero (Figure 1); the actual rotation occurs where the demand curve intersects the  $q$  and  $Q$  axes as  $p$  and  $P^*$  become zero, which from Eqns. (3) and (4) is where  $q = a/b$  and  $Q = A/B = \Gamma^1 a / \Gamma^1 b = q$ . The slope of the new market demand curve becomes  $B = \Gamma^1 b$ . Let us assume cost functions are unchanged. At the new with-insurance equilibrium (denoted with capital letters), from Eqn. (3) we see that  $P^*$  becomes

$$P^* = (A + d)/2 = (\Gamma^1 a + d)/2 \quad (5)$$

so that

$$P^*/p^* = (\Gamma^1 a + d)/(a + d). \quad (6)$$

As long as marginal cost  $d > 0$  and the coinsurance rate follows  $0 < i \leq 1$ , then

$$1 < P^*/p^* < \Gamma^1. \quad (7)$$

Only if marginal cost  $d = 0$  will  $P^*/p^* = \Gamma^1$ . In terms of quantity at the new with insurance equilibrium, from (3) we have that

$$Q^* = (A - d)/2B = (\Gamma^1 a - d)/2 \Gamma^1 b. \quad (8)$$

A bit of algebra reveals that

$$Q^*/q^* = (\Gamma^1 ab - bd) / (\Gamma^1 ab - \Gamma^1 bd) \quad (9)$$

which implies that under insurance, as long as  $b, d > 0$  and  $i < 1$  which implies  $\Gamma^1 > 1$ , the denominator of (9) will be smaller than the numerator, implying that the ratio  $Q^*/q^* > 1$ . Intuitively, the lower is the coinsurance rate  $i$ , the greater is  $Q^*$  relative to  $q^*$  -- equilibrium quantity with insurance relative to no insurance. Graphically, as seen in Figure 1, the effect of coinsurance on price is greater than that on quantity.

There are other possibilities, however. Suppose that the “hardnosed” insurer announced that it would not pay any greater than the pre-insurance reservation price, but that it would provide very generous benefits at lower prices; consumers might also balk at paying the very large upfront insurance policy costs they realized would occur were the insurer be willing to pay prices much greater than the pre-insurance reservation price. Alternatively, as has been argued by some<sup>97</sup>, suppose it was not just the presence of insurance, but the form that it takes that makes demand for drugs under insurance more elastic, as insurers use managed care and formulary bargaining techniques to force

manufacturers to make price concessions. In such an admittedly hypothetical situation, one could simply rotate the demand curve at the reservation price, and make its slope a much flatter  $i$  times the no insurance slope, i.e. specify a new market demand curve as

$$P = a - b'Q = a - ibQ, \text{ where now } b' = ib. \quad (10)$$

Substituting in to Eqn. (3), at the new with “hardnosed” insurance equilibrium (denoted with capital letters and a prime, i.e.  $P'$  and  $Q'$ ), and assuming again no change in cost functions, we see that the equilibrium quantity is  $\Gamma^{-1}$  times the no insurance quantity,

$$Q' = (a - d)/2b' = (a-d)/2 ib = \Gamma^{-1}q^*. \quad (11)$$

However, since  $P' = (a + d)/2$  is not a function of  $b'$ , under this admittedly hypothetical scenario the impact of insurance is only a very large quantity and no price effect. Recall that in contrast, the insurance scenario with the much larger reservation price involves a large price effect and a considerably smaller quantity impact.

Both of these insurance scenarios implicitly contain a number of unrealistic assumptions. While the insurer’s passive acceptance of a reservation price  $\Gamma^{-1}$  times that occurring in a pre-insurance market is unlikely, *a priori* it seems even more unlikely that the insurer would not at least in some cases be willing to pay a higher reservation price than in the no insurance case. The two insurance scenarios likely provide some upper and lower bounds on what is the impact of insurance on price and quantity demanded, with the insurer accepting higher reservation price scenario providing us the most useful intuition and guidance. In such a scenario, if the manufacturer’s profit-maximizing price was  $p^*$  in an uninsured market, the profit maximizing price if everyone has an insurance policy with a coinsurance rate  $i$  is larger than  $p^*$  but less than  $p^*/i$ . How large is the quantity effect relative to the price effect is at this point speculative.

In the case of a drug with therapeutic substitutes, a similar analysis applies; the demand (willingness to pay) for all drugs rises by the factor  $\Gamma^{-1}$ , so the profit-maximizing prices of all drugs will rise by somewhat less than  $\Gamma^{-1}$  times prices in an uninsured market. Moreover, equilibrium quantities will always be greater with than without insurance.

Policies with a non-zero coinsurance rate, however, have now mostly been replaced with copayments for drugs taken orally (i.e., tablets and capsules). A common arrangement is a three or four tier formulary. As of 2008, according to IMS data<sup>98</sup>, a common three tier formulary at a retail pharmacy charged a \$6 copay for generic

medications, \$29 for preferred branded drugs, and \$40 or more for non-preferred branded drugs, all for 30-day prescriptions.<sup>99</sup> The difference between the copayment and the manufacturer’s price is paid through the premium for the policy. The different levels of copayments control relative out-of-pocket prices for various drugs. This shifts demand toward generic drugs and drugs on the formulary; for branded drugs the device of the formulary effectively increases the elasticity of demand faced by the manufacturer (see the chapters by Goldman-Joyce, “Consumer Demand and Health Effects of Cost Sharing”, and by Pauly, “Insurance Design”).

As described above, if there is a fourth tier, instead of a fixed copayment it will have a coinsurance rate  $i$ . As discussed earlier, drugs in this tier are often biologics with high unit prices, e.g., many thousands of dollars for a yearly supply.<sup>100</sup> For such drugs the coinsurance model described above applies.<sup>101</sup>

Some therapeutic classes may have a large number of drugs, but any given patient may only do well on one or a few of them. Analytically, of course, this simply means that the drugs in the class are not close substitutes, and that therefore the manufacturer of each branded drug in the relevant class has substantial market power. Medicare has designated six protected therapeutic drug classes, in which drugs are thought not to be close substitutes. Insurers that participate in Medicare Part D must offer all but one of the drugs in those six classes.<sup>102</sup> In the remaining drug classes insurers must only offer two drugs. Nonetheless, within those classes drugs may have similar effects on the condition being treated but be differentiated by some having fewer side effects (the occurrence of side effects may well vary from person to person) or the frequency with which a patient must take the medication. These differentiating features also give rise to price differences among drugs treating the same condition.

#### *B. The Prescription Drug Insurance Market*

In the U.S. prescription drug insurance benefit services are typically purchased from a pharmacy benefits manager (PBM), usually by the underlying health insurer or as a “carve-out” policy by a large employer. In the latter case the employer may offer medical insurance plans from multiple health insurers but require all of them to use one PBM to prevent selection on the basis of drug formularies or pharmacies. Even if the employer contracts solely with one health insurer so that selection is not relevant, the

employer may carve out the drug benefit to a PBM not affiliated with that insurer because it is more economical.

The American PBM industry has become increasingly concentrated; at the beginning of 2010 it was dominated by three large firms (Caremark/CVS; ExpressScripts; Medco) who had a combined market share of just under 50 percent.<sup>103</sup> Since each of the three large PBMs has substantial bargaining power with manufacturers, this increased concentration has served to increase the price elasticity of demand facing manufacturers with drugs that are highly substitutable within a therapeutic class.

Somewhat over 10 percent of the overall 2008 U.S. pharmaceutical market is accounted for by Medicaid and certain other federal programs such as the Veteran’s Administration, Community Health Centers, and the military medical care system.<sup>104</sup> (This share was larger prior to the implementation of Medicare Part D in 2006; see below.) These government programs purchase prescription drugs under legislation that sets prices to manufacturers as a discount off prices charged to commercial customers. The size of the discount varies by type of drug. As noted above, the 2010 health care reform bill increased the discount off single source drugs (generally those on patent) from 15 to 23.1 percent and off multiple source drugs from 11 to 13 percent.

Scott Morton and Duggan and Scott Morton have demonstrated that these statutorily prescribed discounts have raised prices to other customers.<sup>105</sup> The reason is simple: if a manufacturer lowers price to a commercial customer, the manufacturer also must lower price to the government programs. There will be little or no quantity response in the government market, since quantities are determined by prescribing decisions made by individual physicians who do not face a budget constraint when prescribing. Hence, the optimal price in the commercial market must be greater than it would be without this tie between the commercial and government markets.

### *C. Welfare Implications of Market Power and Insurance*

Deriving welfare implications about drug prices and insurance is difficult for many reasons. A first-best outcome would achieve both static efficiency -- the efficient allocation of drugs on the market at a point in time -- and dynamic efficiency -- the efficient allocation of R&D resources devoted to drugs.

It is best to begin with the simplest, albeit unrealistic case. Assume that the patient is well informed and ignore agency issues with respect to the prescribing physician. Static efficiency requires that price equal the marginal cost of production, which for most drugs will be negligible. Dynamic efficiency, however, requires a price at which the R&D costs can be recouped. (Marketing costs must also be recouped; see below.) Achieving both static and dynamic efficiency simultaneously thus requires some sort of two-part pricing scheme, in which consumers pay little or nothing at the time of purchase, but prices received by manufacturers are sufficiently above marginal production cost to enable them to recoup R&D costs (including R&D on failed drug development efforts).

In principle, of course, drug insurance can achieve just such an efficient outcome. The consumer, or the employer or government on her behalf, pays a premium for the insurance and in turn the consumer receives a heavily discounted price at the time of purchase with the insurer using the proceeds from the premiums to pay the manufacturer a price above the marginal cost of production so that the manufacturer can recover R&D costs. How close or far actual premiums and copayments come to inducing something approximating an economically efficient outcome is not known.<sup>106</sup>

But the conflict between static and dynamically efficient prices is not the only difficulty in attaining an efficient outcome. Consumer ignorance and resulting agency problems are omnipresent in this domain. Because of their relative lack of knowledge and training, by law in the U.S. consumers must obtain a prescription from a physician to purchase most drugs. But the physician also faces costs in acquiring information about drugs, and thus it pays a manufacturer to devote resources to marketing. Although there has been much attention in the general press about direct-to-consumer advertising of prescription pharmaceuticals, the great bulk of pharmaceutical manufacturers’ marketing efforts are directed toward physicians;<sup>107</sup> also see the Kenkel and Mathios chapter in this volume, “Promotion to Physicians and Consumers”. Detailers (pharmaceutical sales representatives) visit physician offices, dispense free samples, pay opinion-leader physicians speaking fees, and offer physicians free “continuing education” - featuring that manufacturer’s products of course – often at resorts or other desirable locations. Such marketing efforts are profitable given typically low marginal production costs,

which implies that any additional quantities of drug sold as a result of marketing efforts can contribute handsomely to profits.<sup>108</sup> Public controversy and lawsuits have occurred alleging that certain marketing practices may be considered unethical, and occasionally illegal. In recent years, manufacturers have entered into a number of settlements involving their marketing efforts.<sup>109</sup>

Marketing efforts directed toward the physician create an agency problem; for example, the physician may rely on the manufacturer’s representatives for information rather than spending the time and effort to seek information from a less biased source, potentially leading to prescribing a less than optimal drug for a patient – or perhaps prescribing when not prescribing at all would be the best treatment. Physician investments in learning about the efficacy, tolerability and safety characteristics of various treatments involves costly investments which the physician must trade off with being able to see more patients and enjoy greater leisure time.

Even if the physician were perfectly informed about the effects of all treatments, however, consumers’ lack of knowledge can be a barrier to efficiency. Suppose the condition being treated has no immediate symptoms – hypertension is an example – but the drug being used to treat the condition has adverse side effects. One possibility in this case is that the side effects are so bad or the consequences of the condition so mild or so far in the future that it is efficient not to take the drug. In this case it can be efficient for the consumer not to take the drug.

But even if it is efficient for the patient to take the drug, there are several barriers. Although the physician can in principle know the clinical consequences on average of taking or not taking the drug, he or she cannot know the patient’s utility function including the patient’s risk aversion. Yet another possibility is simply that the patient is a poor decision maker with respect to probabilistic outcomes, especially in cases in which there is a certain small loss now (e.g., from side effects or simply from the copayments) in return for a larger gain later so the patient simply does not fill the prescription; Frank [2006] considers this and several related situations in the context of behavioral economics. Physicians would characterize this scenario as an adherence or compliance problem. This suggests setting copayments lower than they would be set if all consumers

were excellent decision makers, in effect, providing a greater inducement to comply; some call this “value-based pricing”.<sup>110</sup>

Such a possibility is reinforced if lack of compliance generates greater use of non-drug medical services than would otherwise be the case. If, for example, a person with high blood pressure does not take the appropriate medication, s/he is at higher risk of cardiovascular disease and stroke. In the event of, say, a stroke, there will be additional hospital, physician, and other medical care costs involved when treating the stroke. These costs, which will be mainly borne by others if the patient is insured, can potentially be avoided if the copayment is lowered to induce compliance. This is analogous to raising taxes on cigarettes to deter consumption.<sup>111</sup> An extreme example is directly observed therapy, in which those with an infectious disease (the usual example is tuberculosis) are paid to come in to an office or hospital to be observed taking drugs to treat the disease. In effect, this is a negative copayment.<sup>112</sup>

Value-based pricing has been implemented by a number of benefit plans. Evidence documents that in 2009, although 51.5% of employers surveyed had not adopted any value-based design tool, 28.6% reduced copayments for specific drug classes, 22.7% provided incentives to motivate behavior change, 7.9% reduced copayments for members with specific health conditions, and 6.1% reduced copayments tied to participation in care management programs.<sup>113</sup>

#### **IV. Recent Developments, Issues and Emerging Trends**

We now move on to a discussion of recent developments, controversies and emerging trends. As noted earlier, many drug benefit plans offer tiered formularies; in one recent survey, 86.9% of employers using a formulary have it structured with multiple tiers, with the dominant being three or more tiers, although there is an increasing trend to use four or more tiers (4.7% in 2007, 12.7% in 2009). Coinsurance is giving way to fixed dollar copayments (except for a fourth tier, if it exists); in 2009 (2007), 18.3% (20.9%) of responding employers with multiple tiers utilized a multitier coinsurance design, while 81.7% (79.1%) had multitier fixed dollar copayment provisions.<sup>114</sup> In terms of mail order, the same survey indicated that 96.7% of employers offered access to mail service pharmacy to dispense maintenance medications used to treat chronic conditions, while

17.4% required maintenance medications be dispensed by mail order (“mandatory mail”).<sup>115</sup>

*A. Major Long-Term Trends*

There are very clear trends over time in dollar copayments by tier, less so for coinsurance. As seen in Table 1, between 1998 and 2009, average retail copayment levels increased from \$6.13 to \$9.96, an increase of 62%. Tier 2 average copayments increased even more, from \$11.10 in 1998 to \$25.19 in 2009, an increase of 127%. But Tier 3 average copayments rose the most, from \$17.53 in 1998 to \$42.95 in 2009, an increase of 145%. As expected, the 2009 average retail Tier 4 copayment is even greater at \$62.11, a tier that covers specialty drugs; the PBMI report notes that average copayment levels for “lifestyle” drugs in 2009 was \$36.00.<sup>116</sup>

---

**Table 1**  
**Average Retail Copayment Levels and Coinsurance Rates, by Tier, 1998-2009**

Year	Average Copayment Levels				Average Coinsurance Rates			
	Tier 1	Tier 2	Tier 3	Tier 4*	Tier 1	Tier 2	Tier 3	Tier 4*
1998	\$ 6.13	\$11.10	\$17.53	na	na	na	na	na
1999	7.05	12.82	23.40	na	na	na	na	na
2000	7.17	14.14	27.35	na	19%	21%	42%	na
2001	7.68	16.06	30.51	na	na	na	na	na
2002	8.33	17.57	33.23	na	19%	23%	37%	na
2003	8.66	19.26	35.15	na	20%	26%	40%	na
2004	9.14	20.71	37.45	na	na	na	na	na
2005/6	9.53	21.61	39.06	na	na	na	na	na
2007	8.99	23.08	39.63	na	18%	26%	38%	27%
2008	9.53	24.62	41.13	na	20%	26%	42%	29%
2009	9.96	25.19	42.95	62.11	20%	27%	40%	28%

\*Tier 4 are specialty drugs. na is data not available. Source: 1998-2000 data, Takeda-Lilly [2001]; 2001-3 data, Takeda [2004]; 2004-9 data, Pharmacy Benefit Management Institute [2009].

---

While retail coinsurance rates generally increase from Tier 1 to Tier 3 (roughly, doubling from 20% to 40%), there is no discernable trend over time in Tiers 1 and 3, although there is some evidence suggesting an upward trend in Tier 2 over time.



Interestingly, Tier 4 coinsurance rate data, although available only for the last three years, do not suggest any trend, but at 28% are about the same as Tier 2 coinsurance rates, both being less than the 40% in Tier 3 coinsurance.

In Table 2 we present dollar copayment and coinsurance rate data by tier over time for mail order prescriptions; for daily medications, these are usually 90 days of therapy, three times a monthly amount. Levels and trends differ from retail in several interesting ways. First, for Tier 1 average mail order copayment increased 135% from \$8.62 to \$20.23; relative to 30 day retail, the mail order copayment ratio increased from 1.41 in 1998 to 2.03 in 2009; this might reflect plans’ initially trying to incent patients to obtain three times the number of days of therapy for only 1.4 times the copayment cost, but once having done so, gradually upping the retail copayment, thereby sharing the gains of mail order equally with payer and patient. Between 1998 and 2009, mail order

---

**Table 2**  
**Average Mail Order Copayment Levels and Coinsurance Rates, by Tier, 1998-2009**

Year	Average Copayment Levels				Average Coinsurance Rates			
	Tier 1	Tier 2	Tier 3	Tier 4*	Tier 1	Tier 2	Tier 3	Tier 4*
1998	\$ 8.62	\$15.12	\$26.46	na	na	na	na	na
1999	9.74	17.96	37.67	na	na	na	na	na
2000	10.78	21.29	45.73	na	18%	21%	58%	na
2001	12.60	26.01	55.23	na	na	na	na	na
2002	14.61	31.21	60.61	na	18%	23%	41%	na
2003	16.63	37.33	67.55	na	21%	25%	43%	na
2004	17.18	39.90	74.85	na	na	na	na	na
2005/6	17.95	41.65	77.05	na	na	na	na	na
2007	17.58	47.86	80.80	na	19%	25%	38%	27%
2008	19.23	51.47	85.77	na	19%	25%	40%	26%
2009	20.23	51.70	99.04	117.79	19%	28%	43%	29%

\*Tier 4 are specialty drugs. na is data not available. Source: 1998-2000 data, Takeda-Lilly [2001]; 2001-3 data, Takeda [2004]; 2004-9 data, Pharmacy Benefit Management Institute [2009].

---

copayments increased by a greater percentage for Tier 2 (242%) and Tier 3 (275%) than they did for prescriptions dispensed at retail. With regards to coinsurance, mail order

levels and trends are generally very similar to those at retail. Note that even though there may not be trends over time within each tier in coinsurance rates, to the extent prescription drug prices are increasing, the dollar amounts associated with fixed coinsurance rates increase over time as well.

In Table 3 we report average percent discounts off AWP and average dispensing fees for brands, as reported by employers who are either self-insured or fully insured, separately for retail and mail order. Between 1995 and 2009, both the retail and mail

**Table 3**

**Trends in Retail and Mail Order Reimbursement, 1995 - 2009  
Average Percentage Discounts Off Brand AWP and Average Dispensing Fee**

<u>Year</u>	Retail		Mail Order	
	<u>Discount Off AWP</u>	<u>Dispensing Fee</u>	<u>Discount Off AWP</u>	<u>Dispensing Fee</u>
1995	11.8%	\$2.50	15.0%	\$1.82
1996	12.1	2.47	15.6	1.71
1997	12.6	2.32	16.6	1.61
1998	13.2	2.35	17.1	1.51
1999	13.1	2.30	17.4	1.38
2000	13.5	2.31	18.5	1.15
2001	13.9	2.21	18.9	1.09
2002	14.1	2.13	19.7	0.86
2003	14.5	2.05	20.4	0.52
2004	14.8	1.95	21.0	0.41
2005/6	15.3	1.88	21.9	0.24
2007	16.1	1.88	22.7	*
2008	16.1	1.73	20.2	*
2009	16.4	1.57	23.7	*

Notes: \*In 2008 (2009), only 20.3% (13%) of employers paid dispensing fee on mail prescriptions. For those who did pay a mail dispensing fee, 2007-9 average dispensing fees were \$1.62, \$2.17 and \$3.19, respectively. Data Sources: 1995-2002 data, Takeda [2004]; 2003-9 data, Pharmacy Benefit Management Institute [2009].

order discount off AWP paid by employers to PBMs and pharmacies increased about 50%, not quite five percentage points for retail (from 11.8% to 16.4%), and not quite nine percentage points for mail order (from 15.0% to 23.8%). This increase in discounts over time is consistent both with PBMs gaining bargaining power, and with declining wholesaler margins.

An equally noteworthy trend is the decline in dispensing fees, both for retail and mail order. For retail, the average dispensing fee declined 37% between 1995 and 2009, from \$2.50 to \$1.57. The decline in the average mail order dispensing fee is even more pronounced, falling 87% from \$1.82 in 1995 to \$0.24 in 2005/6. As the notes to Table 4 indicate, by 2008 and 2009, only 20.3% and 13% of employers, respectively, paid a mail order dispensing fee, with 79.7% and 87% providing a zero dispensing fee to mail order service providers.

These trends in retail and mail order dispensing fees, as well as in discounts off AWP, reflect the changing relative bargaining power of PBMs, manufacturers and pharmacies, as well as continuing cost-saving technological advances in information and communication technologies that facilitate electronic communications among them. Two observations are worth noting. First, with discounts off AWP increasing and dispensing fees decreasing, pharmacy gross margins are likely decreasing, at least for transactions involving private sector payers; we discuss this further below. Second, as was noted earlier and documented by numerous CBO and Office of Inspector General Studies, as well as others, reimbursement by public sector payers, particularly Medicaid, have been considerably more generous to pharmacies than have private sector payers, with state Medicaid agencies paying higher dispensing fees and discounting AWP less, both for brand and generic drugs than their private sector counterparts.<sup>117</sup>

In Table 4 we report trends over time in generic dispensing rates – the proportion of all brand plus generic prescriptions dispensed as generics – separately for retail and mail order. Recall that the extent to which generics can be dispensed depends critically on the proportion of patent and off-patent drugs. As the number of new drugs approved by the FDA has generally fallen since their peak numbers in 1995-96, an echo resounds 12-15 years later as they go off patent and encounter generic competition, implying that

the proportion of all distinct molecules that are still patent protected falls over time as well, thereby facilitating increases in generic dispensing rates.<sup>118</sup>

---

**Table 4**  
**Average Retail and Mail Order Generic Dispensing Rates**  
**Percent of Prescriptions Dispensed Through Mail Service, 2000-2009**

Year	Percent Generic Retail	Percent Generic Mail Order	Percent Mail Order	Year	Percent Generic Retail	Percent Generic Mail Order	Percent Mail Order
2000	39.0%	28.0%	14.2%	2006/6	51.0%	39.0%	
2001	40.4			2007	54.5	41.7	18.2*
2002	41.5	31.8	13.0	2008	60.4	49.3	17.8*
2003	44.1	34.0	16.0	2009	63.5	53.6	
2004	47.0	38.0					

Data Sources: 2000 data, Takeda-Lilly [2001]; 2001-2 data, Takeda [2003]; 2003 data, Takeda [2004]; 2004-9 data, Pharmacy Benefit Management Institute [2009]; \*Fein [2009].


---

As seen in Table 4, between 2000 and 2009, retail generic dispensing rates have increased more than 20 percentage points, from 39% to 63.5%, a 63% proportional increase.<sup>119</sup> Although at lower percentage levels in each year than retail, mail order generic dispensing rates have increased proportionately even more, from 28% to 53.6%, a 91% proportional increase. Note that from the vantage point of employers paying drug insurance benefits, since mail order discounts off AWP for on patent brands are greater than those at retail, it is less costly on a per day of therapy basis to have branded maintenance medications for chronic conditions dispensed by mail order than at retail. Thus it is not surprising that the proportion of prescriptions dispensed by brand is greater for mail order (46.4% in 2009) than for retail (36.5%).<sup>120</sup> Another trend worth noting, though at this point based on relatively sparse data, involves the proportion of all prescriptions dispensed via mail order. As seen in Table 4, this proportion appears to be increasing over time, from about 14% at the turn of the century to around 18% by 2009. Note that since mail order dispenses a greater proportion of more costly brands than does

retail, the proportion of revenues flowing through the mail order channel is greater than the proportion of prescriptions.

One final long term trend worth highlighting here is the growth in specialty drugs, primarily (but not exclusively) physician-administered biologics. According to one integrated retailer-PBM, spending on specialty drugs accounted for 12% of all drug spending in 2008, up from 8% three years earlier.<sup>121</sup> To gain bargaining power, retailer-PBM firms are attempting to have their clients exclusively use their network for single-source specialty management for all drugs to treat cancer except those used in hospital settings.<sup>122</sup>

Many of the specialty drugs, however, are used for treating cancer. Fifteen years ago, according to one observer, the only cancer drug on the market that cost more than \$2,500 per month was paclitaxel (Taxol, Bristol-Myers Squibb).<sup>123</sup> As seen in Figure 2 below, the number of cancer drugs charging many times that amount has increased sharply in the last several decades.<sup>124</sup> For example, in 2007 Genentech’s Avastin



**Figure 2: Monthly and Median Costs of Cancer Drugs at the Time of Approval by the Food and Drug Administration (FDA), from 1965 through 2008. Source: Bach [2009].**

(colorectal cancer) cost on average \$42,960, its Herceptin (breast cancer) cost \$27,900, and GlaxoSmith Kline’s Tykerb (breast cancer) cost \$16,575 per course of treatment.<sup>125</sup>

Partly in response to these high unit prices, many Medicare Part D insurers have placed these drugs on a special tier that typically requires 25 percent coinsurance. This induces some demand responsiveness, but the high prices are consistent with a relatively low price elasticity of demand by cancer patients. Medicare, however, covers physician-administered drugs – and many of the cancer drugs are physician administered – under Part B rather than Part D, and Part B has 20% coinsurance. The Part B coinsurance, however, is frequently covered by some kind of supplemental insurance, most often retiree health insurance from a prior employer or Medicaid, in which case the insured may have little or no copayment. The existence of such supplemental insurance likely increases both the profit-maximizing price and quantity of the drugs covered under Part B (see Figure 1).

*B. Emerging Issues and Trends Affecting Pharmaceutical Pricing*

We now move on to a discussion of several prominent emerging issues and trends involving pharmaceutical pricing.

*B.1 Part D, Pharmaceutical Prices and Pharmacy Gross Margins*

As we noted in our theoretical discussion earlier, it is plausible to expect that prices of covered drugs would generally be expected to be greater under insurance than without insurance; the extent of price increase can to some extent be offset depending on how concentrated is the buying and negotiating power of insurers and PBMs acting on behalf of the previously under- and uninsured. Issues regarding the effects of expanded drug coverage on drug prices and pharmacy margins recently emerged again with the implementation of Medicare Part D benefits on January 1, 2006.

Overall, Part D appeared to reduce optimal prices for drugs, which seems contrary to the logic of Figure 1 above.<sup>126</sup> The reason, however, is straightforward: Part D subsidized Medicare beneficiaries to purchase a private insurance plan, and around 90 percent of the individuals enrolled in those plans chose plans with formularies. Before Part D a quarter of Medicare beneficiaries were cash paying customers (i.e., they had no insurance for drugs), whereas after they enrolled in a Part D plan, they in effect had a purchasing agent, the PBM or in Medicare terms the Prescription Drug Plan (PDP), that bargained on their behalf with pharmaceutical manufacturers on the basis of price, using the threat to place any given drug on a higher tier of the formulary in order to obtain a

better price. In short, the demand from the formerly cash-paying segment of the Medicare population became more, not less elastic with the acquisition of insurance, and this drove prices down.

Not surprisingly, utilization of drugs increased post Part D because of the lower out-of-pocket prices paid by consumers. (Although around 75 percent of Medicare beneficiaries had at least some drug insurance before Part D, Part D improved the generosity of the insurance for the majority of them; that is, it lowered the out-of-pocket prices they paid. For example, many Medicare beneficiaries prior to Part D had limits of \$500-1,250 on the amount of drug spending covered in a year.) Duggan and Scott Morton [2010] estimate a large utilization effect from Part D, but it is imprecisely estimated. Zhang et al. [2009] estimate that for a subset of beneficiaries enrolled in an HMO who had no prior drug coverage, utilization increased 74 percent. Moreover, they estimate that for this group the increased cost of drugs was more than offset by decreased costs for hospital and physician spending, most likely because beneficiaries better adhered to the medication regimens prescribed for their chronic diseases. By contrast, another group with reasonably generous drug insurance prior to Part D increased utilization only 11 percent; moreover, hospital and physician spending in this group actually increased, perhaps because the increase in drugs meant too many drugs were now being used with concomitant adverse effects.

As noted by Frank and Newhouse, an additional feature of Part D partially offset the overall downward effect on prices of shifting cash paying customers to PDPs that used a formulary.<sup>127</sup> Specifically, Part D also shifted the drug coverage of those Medicare beneficiaries eligible for both Medicaid and Medicare from Medicaid to PDPs. This meant manufacturers were able to obtain higher prices for this dually eligible group, because they had previously been paid under the discount rules off the best commercial price that we described earlier in this chapter. (The law did not allow the PDPs to buy at the rules governing Medicaid prices for this dually eligible group.) The expectation was that any price rise relative to the best-price Medicaid system would be modest. For unique drugs, however, particularly those used primarily by senior citizens, price increases could have been substantial.

Unfortunately this prediction is impossible to verify directly because AMP and PDP prices are confidential and protected by statute. Hence, one cannot compare Medicaid and PDP prices for drugs heavily used by dual eligibles. Examining Form 10-Q filings with the Securities and Exchange Commission by pharmaceutical firms, however, Frank and Newhouse report that all the manufacturers of branded antipsychotic drugs, 70% of which were purchased by Medicaid prior to 2006, reported “favorable changes in prices that resulted from the shift of large numbers of users of antipsychotic medications from Medicaid to Part D”, leading Frank and Newhouse to conclude “The implication is that prices have increased.”<sup>128</sup>

Frank and Newhouse carried out one other test of this prediction. They compared 2004-6 brand price changes with high shares (55% or more) of elderly purchasers and those with relatively low shares (35% or less) of elderly purchasers. They report that prices for drugs used more heavily by the elderly grew 24.2% over the three years compared with 18.8% for those less heavily used.<sup>129</sup> Moreover, prices of drugs sold to the elderly grew at a more rapid rate after August 2004 (several months after the December 2003 signing of the Part D legislation, but before the January 2006 implementation) than before.<sup>130</sup> These greater price increases for drugs used relatively intensively by the elderly had not been observed in earlier studies, which showed no differences in price inflation for elderly vs. non-elderly intensive drugs, probably because there was no insurance shock analogous to the implementation of Part D.<sup>131</sup>

One other study worth noting in this context is that by Lakdawalla and Yin [2009], who examine whether greater concentration among PDP purchasers offering Part D plans allows them to obtain lower prices for their members. Unlike monopoly power for producers, monopsony power for purchasers can result in consumers’ experiencing price decreases as market power increases – the more enrollees a PDP has, the more bargaining power it has with pharmacies and drug manufacturers – so long as the PDP market does not get so concentrated that PDPs are able to charge consumers a large markup over their costs. Lakdawalla and Yin examine claims data from a large national retail pharmacy. These data contain the drug prices negotiated between the pharmacy and every insurer with which it contracted and cover prescriptions dispensed between September 2004 and April 2007, before and after implementation of Part D on January 1,



2006. They find that insurers that experienced larger enrollment increases due to Part D implementation negotiated lower drug prices with the pharmacy. (Note that the insurer may have been negotiating with the pharmacy on the basis of both its commercial or under 65 business as well as its Medicare business.) More specifically, they find that enrolling an additional 100,000 members is associated with a 2.5% decrease in drug prices and a 5% decrease in pharmacy profits earned on prescriptions filled by enrollees of that insurer. Further, PDPs appear to have used their increased bargaining power to reduce margins at pharmacies for multiple source generic drugs, but were much less successful in leveraging additional enrollments into lower prices for on patent branded drugs.

A closely related issue is the impact of Part D on pharmacy margins. While greater insurance coverage increased overall prescription utilization, benefiting brick and mortar pharmacies, pharmacies’ gross margins could have nonetheless declined following implementation of Part D because they had previously been able to earn very high margins on underinsured and insured cash customers who now had Part D coverage. According to the CVS Caremark 2007 10-K Securities and Exchange Commission filing, in fact pharmacy margins did decline after Part D:

“The Medicare Drug Benefit became effective on January 1, 2006. Since its inception the program has resulted in increased utilization and decreased pharmacy gross margin rates as higher margin business (such as cash and state Medicaid customers) migrated to the new Medicare Part D coverage.”<sup>132</sup>

Similar to their bargaining with drug manufacturers over drug prices, the insurers that sell Part D plans also bargain with pharmacies over dispensing fees. Their bargaining power, however, is constrained by access rules that require 90 percent of urban and suburban Medicare beneficiaries to live within two and five miles, respectively, of a pharmacy.<sup>133</sup> Nonetheless, for the same reason as it did for drug manufacturers, demand facing retail pharmacies likely became more price elastic following the implementation of Part D.

### *B.2 Disintermediating PBMs and Preferred Pharmacy Networks*

Another interesting emerging trend involves the substantial profits earned on generic drugs by both the retail and mail order pharmacy sectors. In September 2006 mass merchandiser giant retailer Wal-Mart announced it was offering a number of 30-day

generic drugs for a price of \$4 per prescription. About a year later Wal-Mart expanded the list of available generic drugs and simultaneously added a new 90-day prescription for a price of \$9 per prescription, implying a dime per day cost of that prescription.<sup>134</sup> A Wal-Mart spokesperson called this the “commoditization” of generic drugs, made possible in part by its buying directly from generic manufacturers and bypassing wholesalers.<sup>135</sup>

Recall that customers with third party insurance usually pay the same copayment regardless of the retail or mail order pharmacy from which they purchase (as long as the pharmacy is in the insurer’s network, which is usually the case). Moreover, as seen in Tables 1 and 2 above, on average in 2007 the Tier 1 copayment for 30 day prescriptions at retail was \$8.99, and for 90-day via mail order was \$17.58, which in both cases is more than twice the cash price offered by Wal-Mart.<sup>136</sup> What Wal-Mart was doing was its classic tactic -- utilizing its enormous purchasing power to underprice its retail competitors, in this case, even underpricing the copayments charged by traditional retail and mail order pharmacies.

For underinsured and uninsured cash paying customers, however, the savings from having their prescriptions dispensed at Wal-Mart could be much larger. According to one observer, a Wal-Mart official stated that while it always files a claim on behalf of its insured customers, it often does not seek reimbursement from payers, even at times waiving dispensing fees offered by Medicaid.<sup>137</sup> Since federal law mandates that pharmacies cannot be reimbursed by Medicaid for more than its Usual & Customary (“U&C”) charges and since these \$4 and \$9 were now clearly Wal-Mart’s U&C charges, when it was seeking reimbursement for dispensing to Medicaid beneficiaries, Wal-Mart typically filed a claim involving smaller reimbursement than that sought by chain and independent retail and mail order pharmacies; state Medicaid agencies thus benefited whenever a beneficiary filled out a prescription at Wal-Mart rather than at other pharmacies.<sup>138</sup> Apparently even at only \$4, at least for the specific generic drugs Wal-Mart had available, the \$4 revenue more than covered Wal-Mart’s acquisition and dispensing costs, generating a positive gross margin.<sup>139</sup> Note that like other pharmacies, Wal-Mart pharmacies have high fixed costs (pharmacy license, pharmacists, insurance, rented space, etc.) relative to the marginal costs of dispensing, implying that as pharmacy

volume increases, even with constant marginal cost, Wal-Mart’s average dispensing cost will fall. Moreover, to the extent the \$4 and \$9 offers incentivized more customers to come to Wal-Mart, the increase in its foot traffic likely had a further positive impact on its non-drug sales and profits.

Within months, a number of other mass merchandisers and food stores, such as Target, Kroger, Safeway and Giant Food, followed Wal-Mart and began offering very low priced generics, aimed particularly at cash customers. The first retail pharmacy chain to respond was Walgreens, which in June 2008 introduced the Walgreens Prescription Savings Club, offering a 3-month supply of over 400 generics for \$12.99 (plus an annual membership fee).<sup>140</sup>

Then in September 2008 Wal-Mart announced an agreement with Peoria, Illinois based Caterpillar by which Wal-Mart would charge a zero copay for Caterpillar’s 70,000 beneficiaries on 2,500 generic drugs, but if Caterpillar’s beneficiaries chose to fill their prescriptions at other retail pharmacies, they would pay the normal \$5 generic copay. Notably, Wal-Mart had 12 stores near Peoria, where most of Caterpillar’s employees lived. Also as part of the agreement, Caterpillar’s PBM (RESTAT) agreed to reimburse Wal-Mart based on Wal-Mart’s actual invoice prices on drugs. The Wal-Mart – Caterpillar agreement not only took away profits from sales of generic drugs at retail and mail order pharmacies, but it also conveyed its potential to disintermediate other PBMs.<sup>141</sup>

With this agreement, Wal-Mart and Caterpillar reintroduced the heavily restricted network differential copayment concept into pharmacy benefits, a concept implemented for hospitals and physicians in the early 1990s with managed care, but later largely discarded because of consumers’ wanting freedom of choice without paying differentially for it. (Insurers continued to have networks, but the great majority of hospitals and physicians were in-network.) Recent news events, however, suggest that employers are returning to a more restrictive or preferred network concept, particularly for physicians and hospitals.<sup>142</sup> Interestingly, in November 2009 Caterpillar announced extension of its preferred pharmacy network effective January 2010, adding Walgreens to Wal-Mart as the only sites at which generic copayments for generic drugs would be zero; at other

pharmacies generic copayments would be higher, and customers would need to initially pay cash, and then fill out various forms to claim reimbursement.<sup>143</sup>

In November 2008, the combined PBM-retail chain CVS-Caremark announced a new Health Savings Plan that let customers buy 90 day supplies of over 400 generics for \$9.99 (plus a \$10 annual enrollment fee) either through its mail order or at its retail sites, calling this “channel neutrality”, and noting that it hoped by shifting its 90-day mail order prescriptions to its retail stores, it would increase foot traffic there.<sup>144</sup>

Notably, these developments involved generic drugs, drugs that have numerous manufacturers competing with each other for sales, and that are still the source of considerable profits for PBMs, mail order and retail pharmacies. As we have noted earlier, the market for on-patent brands is very different, with exclusive manufacturers not having to compete as aggressively on price as do generic manufacturers. Whether discount retailers will team up with other geographically concentrated employers in offering differential copayments and preferred pharmacy networks for on-patent branded products remains to be seen.

### *B.3 Pricing Transparency and Cost-Plus Pricing*

As we have noted many times in this chapter, numerous pharmaceutical-related transactions occur at prices that are not publicly observed. Within health care this is not unique to pharmaceuticals – it also occurs with hospitals and other providers – but for pharmaceuticals it has been a prominent and controversial issue.

In terms of actual acquisition costs, while the Average Sales Price (ASP) is now publicly posted, for new products (including new generics) during the first two quarters on the market, the manufacturer can report WAC as its ASP, and in those two quarters pharmacies and other providers will be reimbursed by Medicare at  $1.06 \times \text{WAC}$ . As actual prices of generics typically fall very rapidly following extensive generic entry, for the two quarters following initial extensive generic entry pharmacies’ actual acquisition costs are likely to be considerably less than WAC, particularly since WAC is a list rather than a transaction price, implying that for these two quarters retail and mail order profits from generics will continue to be substantial.

As we noted earlier, regarding AMP and Medicaid reimbursement, while under the 2010 health care reform legislation the AMP will now be publicly available, the set of

transactions it covers is smaller than before, and as we write this chapter (August 2010) details of how AMP will be determined for new brand and generic products remain to be worked out.

More generally, it should not be surprising that the initial set of pharmaceuticals for which greater transparency in pricing is occurring, particularly in the private sector, is generic drugs. As noted earlier, Wal-Mart and others view generic drugs as being commodities, and in commodity markets with relatively homogenous products, incentives to keep price proprietary are relatively weak; indeed, price competition tends to be particularly strong in commodity markets -- markets that approach the microeconomic ideal of perfect competition. Might certain physician procedures and hospitalizations become “commoditized” in the near future? Walk-in clinics at large retailers may be an embryonic form of such commoditization.<sup>145</sup> The obstacles are considerable, but so too are pressures for cost reductions. We shall see.

One interesting aspect of moving to cost-plus pricing with audited or public actual acquisition costs is a reduction in incentives for pharmacies and PBMs to minimize their costs, and indeed the creation of perverse incentives to increase the cost base on which the “plus factor” is calculated. In the electric utility industry, cost-plus pricing was seen to create incentives for utilities to become too capital intensive, and not aggressively attempt to minimize generation and distribution costs.<sup>146</sup> Will the movement to reimburse pharmacies on cost-plus for generic drugs reduce their incentives to purchase at lowest prices from generic manufacturers?

For branded and other differentiated product markets, particularly for the many pharmaceuticals for which marginal costs are much smaller than average costs and for which consumers’ preferences and valuations are heterogeneous, we can expect that individual manufacturers will find it profitable to employ price discrimination tools, negotiating distinct prices with groups representing beneficiaries with varying demand elasticities, and wanting to keep these transactions price out of the public eye. Indeed, particularly for those organizations such as staff model HMOs (e.g., Kaiser) that have strong bargaining positions due to their restrictive formularies and networks, resulting in ability to move market share, transparent pricing is an undesirable outcome. Rather, for them “the best deal is a secret deal”.<sup>147</sup>

In summary, while the share of prescriptions dispensed as generics has generally been increasing in the U.S. over the last decade, generating substantial margins for retail pharmacies, the introduction of Medicare Part D shifted formerly cash paying customers to insured customers benefiting from the bargaining power of PDPs, thereby reducing manufacturer and retail pharmacy gross margins. Medicare Part D also shifted dual Medicare and Medicaid eligibles from Medicaid to PDPs, increasing revenues for manufacturers but likely decreasing margins for retail pharmacies, as Medicaid reimbursement to pharmacies has traditionally been more generous than that by the private sector insurers. It is likely that demand facing retail pharmacies became more price elastic following the implementation of Part D. A notable recent development is the entry of retail mass merchandiser giants such as Wal-Mart into the low price generic market segment, offering low 30- and 90-day prescription prices, and disintermediating both traditional pharmacy retail chains and PBMs. By offering differentially lower copays at preferred pharmacy networks, the mass merchandise retailers are creating additional price competition for generic pharmaceuticals. Whether the “commoditization” of generic drugs will expand to other types of medical services remains to be seen.

REFERENCES

- Abelson, Reed [2010], “Insurers Push Plans That Limit Health Choices: A Test for the Future”, New York Times, July 18, p. A1.
- Abramson, Richard G., Catherine A. Harrington, Raad Missmar, Susan P. Li and Daniel N. Mendelson [2004], “Generic Drug Cost Containment in Medicaid: Lessons from Five State MAC Programs”, Health Care Financing Review 25(3):25-34, Spring.
- Abrantes-Metz, Rosa M., Christopher P. Adams and Albert D. Metz [2005], “Pharmaceutical Development Phases: A Duration Analysis”, Journal of Pharmaceutical Finance, Economics and Policy 14(4):19-42.
- Adams, Christopher P. and Van V. Brantner [2006], “Estimating the Cost of New Drug Development: Is It Really \$802 Million? Health Affairs 25(2):420-8, March/April.
- Agwunobi, John and Paul A. London [2009], “Removing Costs from the Health Care Supply Chain: Lessons from Mass Retail”, Health Affairs 28(5):1336-42, September/October.
- Aitken, Murray L., Ernst R. Berndt and David M. Cutler [2008], “Prescription Drug Spending: Looking Beyond the Turning Point”, Health Affairs – Web Exclusive 28(1):W151-60, published online December 16, 2008; 10.1377/hlthaff.28.1.W138.
- Alpert, Bill [1996], “Hooked on Drugs: Why Do Insurers Pay Such Outrageous Prices for Pharmaceuticals?”, Barrons, June 10, pp. 15-19.
- American Druggist Blue Book [1969, 1976, 1977], Various annual and semi-annual updates, New York: The Hearst Corporation.
- AmerisourceBergen Corporation [2004], “AmerisourceBergen Corporation – Introduction, Company Histories”, available online at <http://www.enotes.com/company-histories/amerisourcebergen-corporation>, last accessed September 7, 2009.
- Averch, Harvey and Leland L. Johnson [1962], “Behavior of the Firm Under Regulatory Constraint”, American Economic Review 52(5):1052-89, December.
- Bach, Peter B. [2009], “Limits on Medicare’s Ability to Control Rising Spending on Cancer Drugs”, New England Journal of Medicine 360(6):626-33, February 5.
- Berndt, Ernst R. [2001], “The U.S. Pharmaceutical Industry: Why Major Growth In Times Of Cost Containment?”, Health Affairs 20(2):100-14, March/April.
- Berndt, Ernst R. [2002], “Pharmaceuticals in U.S. Health Care: Determinants of Quantity and Price”, Journal of Economic Perspectives 16(4):45-66, Fall.
- Berndt, Ernst R. [2005], Report of Independent Expert Professor Ernst R. Berndt to Judge Patti B. Saris, February 9. United States District Court, District of Massachusetts, In Re Pharmaceutical Industry Average Wholesale Price Litigation, M.D.L. No. 1456, Civil Action No. 01-12257-PBS, Judge Patti B. Saris.
- Berndt, Ernst R. [2007], “A Primer on the Economics of the Re-Importation of Prescription Drugs”, Managerial and Decision Economics 28:415-35.
- Berndt, Ernst R., Iain M. Cockburn, Douglas L. Cocks, Arnold M. Epstein and Zvi Griliches [1998], “Prescription Drug Prices for the Elderly”, Monthly Labor Review 121(9):23-34.
- Berndt, Ernst R., Iain M. Cockburn and Zvi Griliches [1996], “Pharmaceutical

- Innovations and Market Dynamics: Tracking Effects on Price Indexes for Antidepressant Drugs”, Brookings Papers on Economic Activity: Microeconomics 1996(2):1133-88.
- Berndt, Ernst R., Rena N. Denoncourt and Anjali C. Warner [2009], U.S. Markets for Vaccines: Characteristics, Case Studies and Controversies”, Washington DC: AEI Press for the American Enterprise Institute.
- Berndt, Ernst R. and Richard G. Frank [2007], “Medicare Part D and Prescription Drug Prices”, Survey of Current Business 87(6):59-71, June.
- Berndt, Ernst R., Richard Mortimer, Ashoke Bhattacharjya, Andrew Parece and Edward Tuttle [2007], “Authorized Generic Drugs, Price Competition and Consumers’ Welfare”, Health Affairs 26(3):790-9, May/June.
- Brin, Dinah Wisenberg [2009], “Drug-Benefit Cos Said They’ve Adjusted for Price Rollback”, Wall Street Journal, September 17. Available at <http://online.wsj.com/article/BT-CO-20090917-713653.html>, accessed September 18, 2009.
- Calfee, John E. and Elizabeth DuPre [2006], “The Emerging Market Dynamics of Targeted Therapeutics”, Health Affairs 25(5):1302-8, September/October.
- Chernew, Michael E., Allison B. Rosen, and A. Mark Fendrick [2007], “Value-Based Insurance Design,” Health Affairs 26(2):w195-w203.
- Congressional Budget Office [1996], “How the Medicaid Rebate on Prescription Drugs Affects Pricing in the Pharmaceutical Industry”, Washington DC: CBO Papers, January.
- Congressional Budget Office [2004], “Medicaid’s Reimbursement to Pharmacies for Prescription Drugs”, Washington DC: CBO Papers, December. Available at [www.cbo.gov](http://www.cbo.gov).
- Congressional Budget Office [2007], “Prescription Drug Pricing in the Private Sector”, Washington DC: CBO Papers, January. Available at [www.cbo.gov](http://www.cbo.gov).
- Congressional Budget Office [2008], “Increasing Transparency in the Price of Health Care Services and Pharmaceuticals”, Washington DC: CBO Papers, June 5. Available at [www.cbo.gov](http://www.cbo.gov).
- Currie, Janet and Brigitte C. Madrian [1999], “Health, Health Insurance and the Labor Market”, in Orley C. Ashenfelter and David Card, eds., Handbook of Labor Economics, Amsterdam: North Holland.
- CVS Caremark [2009], TrendsRx Report 2009. Caremark. Available at [www.caremark.com](http://www.caremark.com).
- Danzon, Patricia M. [1997], “Price Discrimination for Pharmaceuticals: Welfare Effects in the US and the EU”, International Journal of the Economics of Business 4(3):301-21, November.
- Danzon, Patricia M. and Li-Wei Chao [2000], “Cross-National Price Differences for Pharmaceuticals: How Large and Why?”, Journal of Health Economics 19(2):159-95.
- Danzon, Patricia M. and Mark V. Pauly [2001], “Insurance and New Technology: From Hospital to Drugstore”, Health Affairs 20(5):86-100, September/October.
- Danzon, Patricia M. and Mark V. Pauly [2002], “Health Insurance and the Growth in Pharmaceutical Expenditures”, Journal of Law and Economics 45(2):587-613, October.



- Danzon, Patricia M. and Adrian Towse [2003], "Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents", International Journal of Health Care Finance and Economics 3(3):183-205, September.
- Danzon, Patricia M., Gail R. Wilensky and Kathleen E. Means [2005], "Alternative Strategies for Medicare Payment of Outpatient Prescription Drugs -- Part B and Beyond", American Journal of Managed Care 11(3):173-80, March.
- DiMasi, Joseph A. and Henry G. Grabowski [2007], "The Cost of Biopharmaceutical R&D: Is Biotech Different?", Managerial Decision and Economics 28:469-79.
- DiMasi, Joseph A., Ronald W. Hansen and Henry G. Grabowski [2003], "The Price of Innovation: New Estimates of Drug Development Costs", Journal of Health Economics 22(2):151-86, March.
- DiMasi, Joseph A., Ronald W. Hansen, Henry G. Grabowski and Louis Lasagna [1995], "Research and Development Costs for New Drugs by Therapeutic Category: A Study of the US Pharmaceutical Industry", PharmacoEconomics 7:152-60.
- DiMasi, Joseph A., Ronald W. Hansen, Henry G. Grabowski and Louis Lasagna [1991], "Cost of Innovation in the Pharmaceutical Industry", Journal of Health Economics 10:107-42.
- Drug Channels [2007a], "Wal-Mart adds some \$4 generics (yawn)", Drug Channels, September 27. Available at <http://www.drugchannels.net/2007/09/wal-mart-adds-some4-generics-yawn.html>.
- Drug Channels [2007b], "Wal-Mart's Gain is not Walgreen's Pain", Drug Channels, October 2. Available at <http://www.drugchannels.net/2007/10/wal-marts-gain-is-not-walgreens-pain.html>.
- Drug Channels [2008a], "The AMP Saga Goes On and On and On", Drug Channels, April 25. Available at <http://www.drugchannels.net/2008/04/amp-saga-goes-on-and-on.html>.
- Drug Channels [2008b], "Wal-Mart Redux", Drug Channels, May 7. Available at <http://www.drugchannels.net/2008/05/wal-mart-redux.html>.
- Drug Channels [2008c], "Walgreens' \$4.33 Surrender to Wal-Mart", Drug Channels, June 25. Available at <http://www.drugchannels.net/2008/06/walgreens-433-surrender-to-wal-mart.html>.
- Drug Channels [2008d], "WMT + CAT: Pharmacy's Future?", Drug Channels, September 25. Available at <http://www.drugchannels.net/2008/09/wmt-cat-pharmacs-future.html>.
- Drug Channels [2008e], "New Details on WMT-CAT Pharmacy Deal", Drug Channels, November 6. Available at <http://www.drugchannels.net/2008/11/new-details-on-wmt-cat-pharmacy-deal.html>.
- Drug Channels [2008f], "CVS Escalates the Generic Price War", Drug Channels, November 12. Available at <http://www.drugchannels.net/2008/11/cvs-escalates-generic-price-war.html>.
- Drug Channels [2008g], "The Future of AWP: Ask Again Later", Drug Channels, November 24. Available at <http://www.drugchannels.net/2008/04/amp-saga-goes-on-and-on.html>.
- Drug Channels [2009a], "Healthcare Reform: Bullish for PBMs, but not Pharmacies", Drug Channels, October 20. Available at

- <http://www.drugchannels.net/2009/10/healthcare-reform-bullish-for-pbms-but.html>.
- Drug Channels [2009b], "CAT Rolls Out Preferred WAG-WMT Pharmacy Network", Drug Channels. Available at <http://www.drugchannels.net/2009/12/cat-rolls-out-preferred-wag-wmt.html>.
- Drug Topics Red Book [1970, 1971, 1985, 1992], New York: Topics Publishing Co., Inc.
- Duggan, Mark and Fiona Scott Morton [2006], "The Distortionary Effects of Government Procurement: Evidence from Medicaid Prescription Drug Purchasing", Quarterly Journal of Economics 121(1):1-30.
- Duggan, Mark and Fiona Scott Morton [2010], "The Effect of Medicare Part D on Pharmaceutical Prices and Utilization", American Economic Review 100(1):590-607, March.
- Ellis, Randall P. and Willard G. Manning [2007], "Optimal Health Insurance for Prevention and Treatment," Journal of Health Economics 26(6):1128-50.
- Emissary International LLC [2008], "The Historical Rise of Pharmaceutical Regulation". Available online at <http://www.emissary.com/Focus-on-Clinical-Research-Professionals/history.html>, last accessed 3 July 2010.
- Fay, John T., Jr. [1980], "Wholesale Drug Pricing and Perfect Knowledge", unpublished Ph.D. thesis, Boston MA: Massachusetts College of Pharmacy and Allied Health Sciences, 1980.
- Fay, John T., Jr. [1983], "The Wholesaler", ch. 12 in Mickey C. Smith, Principles of Pharmaceutical Marketing, Third Edition, Philadelphia: Lea & Febiger, pp. 248-71.
- F.D.C. Reports [1966], Two Dominant Trends in Wholesale Drug Business -- Vertical Integration by Adding Manufacturing and Horizontal Merging -- Could Restructure Entire Drug Field", The Pink Sheet, November 14, pp. 3. ff. Adapted and reprinted in part as ch. 15, "Two Dominant Trends in Wholesale Drug Business" in Bernard G. Keller and Mickey C. Smith, eds., [1969] Pharmaceutical Marketing: An Anthology and Bibliography, Baltimore: Williams and Wilkins, pp. 90-93.
- Federal Trade Commission [2009], Authorized Generics: An Interim Report of the Federal Trade Commission, June. Available at <http://www.ftc.gov/opa/2009/06/generics.shtm>, last accessed 14 July 2010.
- Fein, Adam J. [2009], U.S. Pharmacy Industry: 2009 Economic Report and Outlook, Philadelphia, PA: Pembroke Consulting, Inc., September. Available at <http://www.PembrokeConsulting.com/pharmacyEULA.pdf>.
- First DataBank [2009], "AWP Communications re: Update Regarding AWP Litigation -- Final Order and Judgment Entered", March 31. Available at <http://www.firstdatabank.com/Support/awp-communications.aspx>, last accessed July 15, 2010.
- Frank, Richard G. [2001], "Prescription Drug Prices: Why Some Pay More Than Others Do", Health Affairs 20(2):115-28, March/April.
- Frank, Richard G. [2003], "New Estimates of Drug Development Costs", Journal of Health Economics 22(2):325-30.

- Frank, Richard G. [2006], "Behavioral Economics and Health Economics", Economic Institutions and Behavioral Economics, in Peter Diamond and Hannu Vartiainen, eds., Princeton: Princeton University Press.
- Frank, Richard G. and Joseph P. Newhouse [2007], "Mending the Medicare Prescription Drug Benefit: Improving Consumer Choices and Restructuring Purchasing", Washington DC: The Brookings Institution, Hamilton Project Discussion Paper 2007-03, April.
- Frank, Richard G. and Joseph P. Newhouse [2008], "Should Drug Prices Be Negotiated Under Part D of Medicare? And If So, How?", Health Affairs 27(1):33-43, January/February.
- Frank, Richard G. and David S. Salkever [1997], "Generic Entry and the Pricing of Pharmaceuticals", Journal of Economics and Management Strategy 6(1):75-90.
- Fuchs, Victor R. [1974], Who Shall Live?, New York: Basic Books.
- Garber, Alan M., Charles I. Jones and Paul M. Romer [2006], "Insurance and Incentives for Medical Innovation", Cambridge, MA: National Bureau of Economic Research, Working Paper No. W12080, March. Published in Forum for Health Economics & Policy, 2006, Forum: Biomedical Research and the Economy, Article 4.
- Gencarelli, Dawn M. [2002], "Average Wholesale Price for Prescription Drugs: Is There A More Appropriate Pricing Mechanism?", National Health Policy Forum, Issue Brief No. 775, June 7. Washington DC: George Washington University.
- Golden, Joshua [2008], "Assessing the First DataBank Settlement: Dramatic Shake-Up or Status Quo?", Benefits Quarterly, Fourth Quarter 2008:12-15. Available at [www.hewittassociates.com](http://www.hewittassociates.com), last accessed 12 July 2010.
- Goldman, Dana P., Geoffrey F. Joyce, Grant Lawless et al. [2006], "Benefit Design and Specialty Drug Use", Health Affairs 25(5):1319-31, September/October.
- Goldman, Dana P. and Tomas J. Philipson [2007], "Integrated Insurance Design in the Presence of Multiple Medical Technologies," American Economic Review 97(2):427-32.
- Gorman, Joseph B. [1971], Kefauver: A Political Biography, New York: Oxford University Press.
- Grabowski, Henry G. [2008], "Follow-on Biologics: Data Exclusivity and the Balance Between Innovation and Competition", Nature Reviews: Drug Discovery 7:479-88, June, doi:10.1038/nrd2532.
- Grabowski, Henry G., Iain M. Cockburn and Genia Long [2006], "The Market for Follow-On Biologics: How Will It Evolve?", Health Affairs 25(5):1
- Greenberg, R.B. [1988], "The Prescription Drug Marketing Act of 1987", American Journal of Hospital Pharmacy 45(10):2118-26, November.
- Green Sheet [1971], "Actual Acquisition Cost Should Replace 'Average Whsle. Price'", Weekly Pharmacy Reports, Pharmacy Reports, Inc., March 22.
- Gruber, Jonathan [2000], "Health Insurance and the Labor Market", ch. 12 in Anthony J. Culyer and Joseph P. Newhouse, eds., Handbook of Health Economics, Amsterdam: North-Holland, 645-706.
- Gruber, Jonathan and Botond Koszegi [2001], "Is Addiction Rational? Theory and Evidence," Quarterly Journal of Economics 116(4):1261-1305.

- Harris, Gardiner [2009], "Pfizer Pays \$2.3 Billion to Settle Marketing Case", New York Times, September 2. Available online at [http://www.nytimes.com/2009/09/03/business/03health.html?\\_r=1&pagewanted=print](http://www.nytimes.com/2009/09/03/business/03health.html?_r=1&pagewanted=print), last accessed July 10, 2010.
- Hyman, Phelps & McNamara [2008]. "First DataBank Announces New Settlement in AWP Litigation", FDA Law Blog, June 24. Available at [http://www.fdalawblog.net/fda\\_law\\_blog\\_hyman\\_phelps/2008/06/first-databank.html](http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2008/06/first-databank.html), last accessed July 12, 2010.
- Keeler, Emmett B., Joseph P. Newhouse, and Charles E. Phelps [1977], "Deductibles and Demand: A Theory of the Consumer Facing a Variable Price Schedule under Uncertainty," Econometrica 45(3): 641-655.
- Keller, Bernard G., Jr. [1969], "The Modern Drug Wholesaler", ch. 14 in Bernard G. Keller, Jr., and Mickey C. Smith, eds., Pharmaceutical Marketing: An Anthology and Bibliography, Baltimore: The Williams and Wilkins Co., pp. 85-93.
- Kolassa, E. M. (Mick) [1997], Elements of Pharmaceutical Pricing, Binghamton NY: The Pharmaceutical Products Press.
- Kolassa, E. M. (Mick) [2009], The Strategic Pricing of Pharmaceuticals, The PondHouse Press.
- Kolassa, Mick [1994], "Guidance for Clinicians in Discerning and Comparing the Price of Pharmaceutical Agents", Journal of Pain and Symptom Management 9(4):235-43, May.
- Kyle, Margaret K. [2007], "Pharmaceutical Price Controls and Entry Strategies", Review of Economics and Statistics 89(1):88-99.
- Kyle, Margaret K. [2009], "Parallel Trade in Pharmaceuticals: Firm Responses and Competition Policy", ch. 13 in Barry Hawk, ed., International Antitrust Law & Policy, New York: Juris Publishing for the Fordham Competition Law. Available from <http://margaretkyle.net/IntlAntitrust.pdf>, last accessed July 10, 2010.
- Kyle, Margaret K. [2010], "Strategic Responses to Parallel Trade", unpublished working paper, Toulouse School of Economics, May (revision of National Bureau of Economic Research Working Paper No. 12968). Available from [http://margaretkyle.net/Strategic\\_Responses.pdf](http://margaretkyle.net/Strategic_Responses.pdf), last accessed July 10, 2010.
- Lakdawalla, Darius and Wesley Yin [2009], "How Insurers' Bargaining Power Affects Drug Prices in Medicare Part D", Cambridge MA: National Bureau of Economic Research, Working Paper No. 15330, April.
- Martinez, Barbara [2006], "How Quiet Moves by a Publisher Sway Billions in Drug Spending", Wall Street Journal, October 6, p. A1.
- "Medicaid Commission". Report to the Honorable Secretary Michael O. Leavitt, Department of Health and Human Services and the United States Congress, September 1, 2005. Available at <http://aspe.hhs.gov/medicaid/090105rpt.pdf>.
- Morgan Lewis [2010], "Price Reporting and Governmental Rebate Issues Arising from the Healthcare Reform Law -- An Early Assessment", Morgan Stanley LawFlash, July 6. Available at <http://www.morganlewis.com/healthcarereform>.
- Mossinghoff, Gerald J. [1999], "Overview of the Hatch-Waxman Act and Its Impact on the Drug Development Process", Food and Drug Law Journal 54(2):187-94.

- National Association of Chain Drug Stores [2010], "Industry Stats". Available at [http://www.nacds.org/wmsprint.cfm?print\\_url=http%3A//www.nacds.org/wmspage.cfm%3...](http://www.nacds.org/wmsprint.cfm?print_url=http%3A//www.nacds.org/wmspage.cfm%3...), last accessed August 4, 2010.
- National Association of State Medicaid Directors [2010], "Post AWP Pharmacy Pricing and Reimbursement", June/
- National Community Pharmacy Association [2006], "First DataBank (FDB) Lawsuit and Proposed AWP Settlement -- FAQ", available at [www.ncpanet.org/pdf/legal/legal\\_1stdbpal-faw.pdf](http://www.ncpanet.org/pdf/legal/legal_1stdbpal-faw.pdf).
- National Pharmaceutical Council [2003], Pharmaceutical Benefits 2003.
- Needles, Zack [2008], "McKesson Settles Class Action Suit for \$350 Million", Law.Com, November 24. Available at <http://www.law.com/jsp/laww/LawArticleFriendly.jsp?id=1202426232278>.
- Newhouse, Joseph P. and Anna D. Sinaiko [2008], "What We Know and Don't Know About the Effects of Cost Sharing on Demand for Medical Care - and So What?" in Frank A. Sloan and Hirschel Kasper, eds., Incentives and Choice in Health Care, Frank A. Sloan and Hirschel Kasper, Cambridge, MA: MIT Press, pp. 156-84.
- Peltzman, Sam [1973], "An Evaluation of Consumer Protection Legislation: The 1962 Drug Amendments", Journal of Political Economy 81(5), September-October.
- Pennebaker, George [1998], "The Rest of the AWP Story", ComputerTalk 18(1):6-7, January/February.
- Pharmacy Benefit Management Institute [2009], 2009-2010 Prescription Drug Benefit Cost and Plan Design Report, Scottsdale AZ. Available from [www.pbmi.com](http://www.pbmi.com).
- Phelps, Charles E. and Joseph P. Newhouse [1974], "Coinsurance, The Price of Time, and the Demand for Medical Services", Review of Economics and Statistics 56(3):334-42, August.
- Reiffen, David E. and Michael E. Ward [2005], "Generic Drug Industry Dynamics", Review of Economics and Statistics 87(1):37-49.
- Reiffen, David E. and Michael E. Ward [2007], "'Branded Generics' As A Strategy to Limit Cannibalization of Pharmaceutical Markets", Managerial and Decision Economics 28:251-65.
- Rosenthal, Meredith B., Ernst R. Berndt, Julie M. Donohue, Richard G. Frank and Arnold M. Epstein [2002], "Promotion of Prescription Drugs to Consumers", New England Journal of Medicine 346(7):498-505, February 14.
- Saha, Atanu, Henry G. Grabowski, Howard M. Birnbaum, Paul E. Greenberg and Oded Bizan [2006], "Generic Competition in the U.S. Pharmaceutical Industry", International Journal of the Economics of Business 13(1):15-38, February.
- Saris, Judge Patti B. [2009], "Memorandum and Order", in re: New England Carpenters Health Benefit Fund, et al., Plaintiffs, v. First Databank, Inc. and McKesson Corporation, Defendants, Civil Action No. 05-11148-PBS, and District Council 37 Health and Security Plan, on behalf of itself and all others similarly situated, Plaintiff, v. Medi-Span, a division of Wolters Kluwer Health, Inc., Defendant, Civil Action No. 07-10988-PBS, March 17, pp. 5-6. Available at <http://www.firstdatabank.com/download/pdf/OrderGrantingFinalApprovalofSettlement031709.pdf>.
- Scherer, F. Michael [1997], "How US Antitrust Can Go Astray: The Brand Name

- Prescription Drug Litigation", International Journal of the Economics of Business 4(3):239-56, November.
- Schondelmeyer, Stephen W. and Marian V. Wrobel [2004], Medicaid and Medicare Drug Pricing: Strategy to Determine Market Prices, Cambridge, MA: Abt Associates, Inc., August 30. Available online at [www.abtassociates.com/reports/20040830\\_500\\_00\\_0049.pdf](http://www.abtassociates.com/reports/20040830_500_00_0049.pdf).
- Scott, Mary Kate [2006], "Health Care in the Express Lane: The Emergence of Retail Clinics". Available online at <http://www.chcf.org/~media/Files/PDF/H/HealthCareInTheExpressLaneRetailClinics.pdf>.
- Scott Morton, Fiona [1997], "The Strategic Response by Pharmaceutical Firms to the Medicaid Most-Favored-Customer Rules", RAND Journal of Economics 28(2):269-90, Summer.
- Scott Morton, Fiona [1999], "Entry Decisions in the Generic Pharmaceutical Industry", RAND Journal of Economics 30:421-40.
- Scott Morton, Fiona [2000], "Barriers to Entry, Brand Advertising, and Generic Entry in the U.S. Pharmaceutical Industry", International Journal of Industrial Organization 18:1085-1104.
- Schwartz, Victor E., Cary Silverman, Michael J. Hulka and Christopher E. Appel [2009], "Marketing Pharmaceutical Products in the Twenty-First Century: An Analysis of the Continued Viability of Traditional Principles of Law in the Age of Direct-to-Consumer Advertising", Harvard Journal of Law & Public Policy 32(1):333-88.
- Showalter, Mark H. [1999], "Firm Behavior in a Market with Addiction: The Case of Cigarettes", Journal of Health Economics 18:409-27.
- Shrank, William H., Niteesh K. Choudhry, Jessica Agnew-Blas et al. [2010], "State Generic Substitution Laws Can Lower Drug Outlays Under Medicaid", Health Affairs 29(7):1383-90, July.
- Siecker, Bruce [19??], "Place Applications in the U.S. Drug Market", ch.12 in Mickey C. Smith, E. M. "Mick" Kolassa, Greg Perkins and Bruce Siecker, eds., Pharmaceutical Marketing: Principles, Environment, and Practice, publisher?
- Silverman, Ed [2008], "Pharmacies Fight First DataBank Settlement", Pharmalot.com, January 7. Available at <http://www.pharmalot.com/2008/01/pharmacies-fight-first-databank-settlement/>, last accessed July 12, 2010.
- Smith, Mickey C. [1975], "The Wholesaler", ch. 12 in Principles of Pharmaceutical Marketing, Second Edition, Philadelphia: Lea & Febiger, pp. 221-71.
- Takeda [2003], The Prescription Drug Benefit Cost and Plan Design Survey Report Provided by Takeda, 2003 Edition, Temple AZ: Pharmacy Benefit Management Institute, Inc. Available from [pbmi@pbmi.com](mailto:pbmi@pbmi.com).
- Takeda [2004], The Prescription Drug Benefit Cost and Plan Design Survey Report, 2004 Edition, Temple AZ: Pharmacy Benefit Management Institute, Inc. Available from [pbmi@pbmi.com](mailto:pbmi@pbmi.com).
- Takeda-Lilly [2001], The Takeda and Lilly Prescription Drug Benefit Cost and Plan Design Survey Report, 2001 Edition, Temple AZ: Pharmacy Benefit Management Institute, Inc. Available from [pbmi@pbmi.com](mailto:pbmi@pbmi.com).
- Trusheim, Mark R., Murray L. Aitken and Ernst R. Berndt [2010], "Characterizing

- Markets for Biopharmaceutical Innovations: Do Biologics Differ From Small Molecules?”, Cambridge, MA: National Bureau of Economic Research, Working Paper No. 16014, May. Forthcoming, Forum for Health Economics & Policy.
- Trusheim, Mark. R., Ernst R. Berndt and Frank L. Douglas [2007], “Stratified Medicine: Strategic and Economic Implications of Combining Drugs and Clinical Biomarkers”, Nature Reviews Drug Discovery 6(4):287-93.
- United States Department of Health and Human Services [2010], “Glossary of Pharmacy-Related Terms”, Health Resources and Services Administration. Available online at <http://www.hrsa.gov/opa/glossary.htm>, last accessed July 7, 2010.
- United States Department of Health and Human Services [1997a], “Medicaid Pharmacy – Actual Acquisition Costs of Prescription Drug Products for Brand Name Drugs”, Office of Inspector General, Report A-06-96-00030, April. Available online through [www.oig.hhs.gov/reports.htm](http://www.oig.hhs.gov/reports.htm).
- United States Department of Health and Human Services [1997b], “Excessive Medicare Payments for Prescription Drugs”, Office of Inspector General, Report OEI-0e-97-00290, December. Available online through [www.oig.hhs.gov/reports.htm](http://www.oig.hhs.gov/reports.htm).
- United States Department of Health and Human Services [2001], “Medicaid Pharmacy – Actual Costs of Brand Name Prescription Drug Products”, Office of Inspector General, Report A-06-00-00023, August. Available online through [www.oig.hhs.gov/reports.htm](http://www.oig.hhs.gov/reports.htm).
- United States Department of Health and Human Services [2002], “Medicaid Pharmacy – Actual Acquisition Costs of Generic Prescription Drug Products”, Office of Inspector General, Report A-06-01-00053, March. Available online through [www.oig.hhs.gov/reports.htm](http://www.oig.hhs.gov/reports.htm).
- United States Department of Health and Human Services [2004a], “Omission of Drugs from the Federal Upper Limit List in 2001”, Office of Inspector General, Report OEI-03-02-00670, February. Available online through [www.oig.hhs.gov/reports.htm](http://www.oig.hhs.gov/reports.htm).
- United States Department of Health and Human Services [2004b], “Variation in State Medicaid Drug Prices”, Office of Inspector General, Report OEI-05-02-00681, September. Available online through [www.oig.hhs.gov/reports.htm](http://www.oig.hhs.gov/reports.htm).
- United States Federal Trade Commission [2009], Emerging Health Care Issues: Follow-on Biologic Drug Competition, June. Available online at [www.ftc.gov/opa/2009/06/biologics.shtru](http://www.ftc.gov/opa/2009/06/biologics.shtru).
- United States Food and Drug Administration [nd], “Therapeutic Equivalence Evaluations Codes”, in Orange Book Preface, Center for Drug Evaluation and Research, Approved Drug Products with Therapeutic Equivalence Evaluations, 30<sup>th</sup> Edition.
- United States General Accounting Office [1993], “Medicaid: Changes in Drug Prices Paid by HMOs and Hospitals Since Enactment of Rebate Provisions”, GAO/HRD-93-43, January.
- United States General Accounting Office [2001], “Medicare: Payments for Covered Outpatient Drugs Exceed Providers’ Cost”, Report to Congressional Committees, GAO-01-1118, September.
- Varian, Hal R. [1989], “Price Discrimination”, ch.10 in Richard L. Schmalensee and Robert D. Willig, eds., Handbook of Industrial Organization, Vol. 1:597-654.

- Wal-Mart [2010], “\$4 Prescriptions Program”, available online at <http://www.walmart.com/cp/4-Prescriptions-Program/546834>, last accessed March 21, 2010.
- Weinstein, Roy and John Culbertson [1997], “How US Antitrust Can Be On Target: The Brand Name Prescription Drug Litigation”, International Journal of the Economics of Business 4(3):257-64, November.
- Wolters Kluwer Health [2010], “Pricing Policy Update: Important Notice for Wolters Kluwer Health’s MediSpan Customers”. Available online at <http://www.medispan.com/Pricing-Policy-Update.aspx>, last accessed July 27, 2010.
- Zhang, Yuting, Julie M. Donohue, Judith R. Lave et al. [2009], “The Impact of Medicare Part D Drug Benefit on Pharmacy and Medical Care Spending”, New England Journal of Medicine 361(1):52-61.



## ENDNOTES

<sup>1</sup> <http://www.cms.gov/NationalHealthExpendData/downloads/tables.pdf>.

<sup>2</sup> See Gruber [2000] and Currie and Madrian [1999].

<sup>3</sup> The 37 percent is a conservative estimate because the National Health Accounts define the subsidies that the federal government pays private employers who maintain credible drug coverage for their retirees a subsidy. These subsidies are defined as Private Health Insurance costs in the Accounts and not public sector pharmaceutical spending, though they arguably should be classified with prescription drug spending; if there were no Medicare Part D drug benefit, these subsidies would not exist.

<sup>4</sup> Although it is commonly believed that US unit prices are well above those in the rest of the world, this is not the case; a market basket of US prices (including brands and generics) is slightly lower than Canadian and 24 percent lower than German prices, although higher than prices in a number of other countries. See Danzon and Chao [2000].

<sup>5</sup> As described in Gorman [1971].

<sup>6</sup> For further details, see, for example, Gorman [1971], Peltzman [1973], Emissary International [2008], and Schwartz, Silverman, Hulka and Appel [2009].

<sup>7</sup> See, for example, F.D.C. Reports [1966].

<sup>8</sup> Mossinghoff [1999].

<sup>9</sup> The FDA assigns an AA, AN, AO, AP or AT rating, depending on the dosage form, when there are no known or suspected bioequivalence problems, and an AB rating when actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. Various B ratings, e.g., BC, BD, BE, BN, etc. are drug products for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence. See U.S. Food and Drug Administration, Orange Book Preface, p. 4 for more details.

<sup>10</sup> For the small number of patients who have allergies to certain colors, lactose intolerance or other reactions with the inactive ingredient of a small molecule, a brand and an AB-rated bioequivalent generic drug may in fact generate clinically significant different patient responses.

<sup>11</sup> Reiffen and Ward [2005], Saha, Grabowski, Birnbaum, Greenberg and Bizan [2006].

<sup>12</sup> If there are several formulations of the molecule having different strengths, it is possible that there will be different successful Paragraph IV entrants for each strength. Further details and references regarding Paragraph IV certifications are given in Berndt, Mortimer, Bhattacharjya, Parece and Tuttle [2007].

<sup>13</sup> For discussion, see Federal Trade Commission [2009].

<sup>14</sup> Berndt, Mortimer, Bhattacharjya, Parece and Tuttle [2007].

<sup>15</sup> See Berndt, Cockburn and Griliches [1996] for examples.

<sup>16</sup> For a comparison of small molecules and biologics, see Trusheim, Aitken and Berndt [2010].

<sup>17</sup> For discussion and references, see, for example, Grabowski, Cockburn and Long [2006], Grabowski [2008] and United States Federal Trade Commission [2009].

<sup>18</sup> It is notable that for vaccines – among the largest biologic molecules – in the U.S. there has not been any generic vaccine marketed. For discussion of vaccine markets and comparisons with small molecules and other biologics, see Berndt, Denoncourt and Warner [2009].

<sup>19</sup> Schondelmeyer and Wrobel [2004].

<sup>20</sup> The use and marketing of AWP, WAC, and other prices has been the subject of considerable litigation, in which one of the current authors (ERB) has been involved. See Berndt [2005] for definitions and histories of the various list prices. The National Association of Chain Drug Stores [2010] reports that in 2009 an average retail prescription was priced at \$76.94, of which the manufacturer receives \$61.27 (79.6% of price), the wholesaler receives \$2.33 (3.0% of price), and the retailer receives \$13.33 (17.3% of price). The average brand prescription price was \$155.45, while that for a generic was \$39.73.

<sup>21</sup> Berndt [2001,2002]; Frank [2001].

<sup>22</sup> For further discussion, see Frank [2001] and Berndt [2002].

<sup>23</sup> Variants of formularies, and examples of historical copayment trends, are given in Frank [2001] and Berndt [2002].

<sup>24</sup> Much of the material presented here regarding AWP and other prices is discussed in greater detail in Berndt [2005]. For a detailed discussion of various pharmaceutical prices, see Kolassa [2009], especially ch. 3.

---

<sup>25</sup> The paragraphs that follow regarding the creation and evolution of AWP are based in large part on Pennebaker [1998] and a half-day meeting between one of the authors (ERB) and Pennebaker on August 28, 2009. George Pennebaker, PharmD, is now a retired consultant, and can be reached at 916-501-6541, or at [george.pennebaker@sbcglobal.net](mailto:george.pennebaker@sbcglobal.net). Reference to the role California Medicaid played in creating AWP is also made in Martinez [2006], citing E. M. “Mick” Kolassa; also see Kolassa [2009], especially ch. 3.

<sup>26</sup> ERB discussion with Pennebaker, August 28, 2009, in Boston, MA.

<sup>27</sup> In cases where the manufacturer did not suggest a retail selling price nor established a fair trade minimum, the Red Book column entry was left blank. See, for example, Drug Topics Red Book [1970].

<sup>28</sup> Drug Topics Red Book [1970].

<sup>29</sup> Drug Topics Red Book [1970].

<sup>30</sup> See, for example, Drug Topics Red Book [1971, 1985, 1992].

<sup>31</sup> American Druggist Blue Book [1975, p. 1, 340; 1976, p. 67, 446].

<sup>32</sup> American Druggist Blue Book [1997, p. 436].

<sup>33</sup> American Druggist Blue Book [1995, p. 5].

<sup>34</sup> ERB discussion with Pennebaker, August 28, 2009, in Boston, MA. There is evidence that already in 1971, the California legislature’s fiscal consultant recognized that AWP overstated pharmacy’s actual acquisition costs. The Green Sheet [1971, p. 3] reports that the consultant’s report stated that “Most discounts are in the 10% range.”

<sup>35</sup> Kolassa [1994, pp. 236-7]; much of this material is reproduced in Kollassa’s 1997 textbook, Kolassa [1997, pp. 33, 35-6]. Independent verification of Kolassa’s observation is provided in Fay [1980, p. 51].

<sup>36</sup> Fay [1980], pp. 29, 32, 34.

<sup>37</sup> Fay [1980], pp. 26, 29, 32, 34.

<sup>38</sup> Ibid.

<sup>39</sup> Fay [1980, pp. 125-6] reports, “For the period 1977-1979, an examination of NWDA records and other sources indicates that some 25 warehouses were closed to consolidate service in larger trading areas, 11 were either merged or acquired and 13 ceased operations for one business reason or another, usually a financial problem. There is general agreement in the industry that the number of locations will continue to decline and that the trend to mergers and acquisitions will accelerate [footnote reference omitted]...Active members of NWDA operated from 367 locations in 1970. The comparable number for these same firms was 265 in 1979.”

<sup>40</sup> Fay reports that in 1979 a typical wholesaler was receiving orders for 42% of its sales volume electronically, “with 60 percent a reasonable estimate for 1980.” (p. 45). Additional details on the electronic transformation of wholesaling are given in ch. 5 of Fay’s 1980 Ph.D. dissertation.

<sup>41</sup> See especially “Computers as Agents of Change” (pp. 61-5) and “Retailing Reorganized” (pp. 65-7) in Fay [1983]. For one wholesaler company’s historical description of its experience in exploiting opportunities brought about by the ever lower cost information and communications technologies, see Amerisource Bergen Corporation[2004].

<sup>42</sup> United States Department of Health and Human Services [1997a].

<sup>43</sup> United States Department of Health and Human Services [1997b].

<sup>44</sup> United States Department of Health and Human Services [2001].

<sup>45</sup> United States Department of Health and Human Services [2002].

<sup>46</sup> Congressional Budget Office [1996], p. 19, referring to United States General Accounting Office [1993].

<sup>47</sup> Congressional Budget Office [2004], p. 1.

<sup>48</sup> Congressional Budget Office [2004], p. 1.

<sup>49</sup> Kolassa [1994], p. 237; Alpert [1996].

<sup>50</sup> Online at <http://www.usdoj.gov/atr/public/busreview/0772.htm>, pp. 1,2. This was a portion of Bingaman’s October 1, 1993 response indicating that “the Department currently intends to bring suit to challenge the program if PMA and its members go forward with this proposal.” Earlier, following Merck’s 1990 announcement of a voluntary commitment to limit annual price increases to no more than the growth in the overall Consumer Price Index (“CPI”), several other pharmaceutical companies followed suit. In 1993 the Pharmaceutical Manufacturers Association (“PMA”) requested a business review by the U.S. Department of Justice of a program it proposed to implement, whereby member companies would commit to limiting annual price increases at rates not to exceed growth in the CPI, subject to audit.

<sup>51</sup> United States General Accounting Office [2001], pp. 23-24.

<sup>52</sup> Medicaid Commission [2005].

- <sup>53</sup> See Gencarelli [2002] and the references cited therein for further details.
- <sup>54</sup> Gencaarelli [2002], National Pharmaceutical Council [2003], Abramson, Harrington, Missmar et al. [2004] and U.S. Department of Health and Human Services [2004a,b].
- <sup>55</sup> Drug Channels [2008a].
- <sup>56</sup> Morgan Lewis [2010].
- <sup>57</sup> Morgan Lewis [2010]. Bona fide service fees are excluded from the AMP calculations.
- <sup>58</sup> Danzon, Wilensky and Means [2005].
- <sup>59</sup> United States Department of Health and Human Services, Health Resources and Service Administration [2010].
- <sup>60</sup> United States General Accounting Office [2001], p. 23.
- <sup>61</sup> United States Department of Health and Human Services, Health Resources and Services Administration [2010].
- <sup>62</sup> Martinez [2006].
- <sup>63</sup> Saris [2009]. References and paragraph breaks from Judge Saris’ order have been omitted.
- <sup>64</sup> Martinez [2006].
- <sup>65</sup> Martinez [2006]. This article also states that Morgan’s testimony contradicted accounts of the two other largest wholesalers, AmerisourceBergen and Cardinal Health, who stated they hadn’t provided pricing information in earlier years either.
- <sup>66</sup> Silverman [2008].
- <sup>67</sup> Needles[2008]; Drug Channels [2008g].
- <sup>68</sup> First DataBank [2009]. Additional terms of the settlement required FDB to establish a centralized data repository to facilitate reasonable access to other pending FDB litigation, make a \$1 million contribution for benefit of settlement class members, and pay \$1.1 million in attorneys’ fees and other expenses. A separate settlement was also reached with publisher Medi-Span, a division of Wolters Kluwer Health, Inc., to apply the same rollback to all other drugs whose AWP was in excess of 120% of WAC.
- <sup>69</sup> Hyman, Phelps & McNamara [2008].
- <sup>70</sup> National Community Pharmacy Association [2006]. Also see National Association of State Medicaid Directors [2010].
- <sup>71</sup> Silverman [2008].
- <sup>72</sup> Golden [2008], p. 13.
- <sup>73</sup> Brin [2009].
- <sup>74</sup> Fein [2009], p. 35.
- <sup>75</sup> See National Association of State Medicaid Directors [2010].
- <sup>76</sup> Wolters Kluwer Health [2010].
- <sup>77</sup> See Frank [2001] for an overview discussion and application.
- <sup>78</sup> Phelps and Newhouse [1974].
- <sup>79</sup> The discussion that follows is based largely on Greenberg [1988].
- <sup>80</sup> Hospitals can return drug products, provided the return is made to the manufacturer or wholesaler and provided written notice is secured that the goods were received (for manufacturers) or the goods were destroyed or returned to the manufacturer (for wholesalers). See Greenberg [1988] for further details.
- <sup>81</sup> For further discussion of the economics of reimportation, see Berndt [2007].
- <sup>82</sup> Fuchs [1974] describes price discrimination by pharmaceutical manufacturers, stating “maximum profits are realized by cutting prices where sales are likely to be responsive to such cuts and by maintaining them in all other markets” (p. 109). He goes on to state, “More than half of all the drugs sold by retailers come to them through drug wholesalers, whose markup is usually small (about 10 percent of the retail price) and covers the cost of such essential functions as storage, credit and delivery. Unlike drug manufacturing and drug retailing, the wholesaling sector of the drug business has never seemed to pose any special problems for public policy.” (p. 112).
- <sup>83</sup> DiMasi, Hansen, Grabowski and Lasagna [1991], DiMasi, Hansen , Grabowski [2003]; also see Adams and Van Brantner [2006].
- <sup>84</sup> See, for example, Abrantes-Metz, Rosa M., Christopher P. Adams and Albert D. Metz [2005], and DiMasi, Hansen, Grabowski and Lasagna [1995].
- <sup>85</sup> DiMasi and Grabowski [2007].
- <sup>86</sup> Aitken, Berndt and Cutler [2008]; Berndt, Cockburn and Griliches [1996].

<sup>87</sup> For a discussion of various components of variable costs for biopharmaceuticals, see Berndt [2002]. These conditions also create strong incentives for pharmaceutical manufacturers to engage in vigorous marketing efforts, including traditional detailing to physicians and direct-to-consumer advertising (Berndt [2001]).

<sup>88</sup> Frank [2001]; Schondelmeyer and Wrobel [2004].

<sup>89</sup> For a survey of the welfare economics of price discrimination, see Varian [1989].

<sup>90</sup> See, for example, F. Michael Scherer [1997] and Patricia M. Danzon [1997].

<sup>91</sup> See, for example, Weinstein and Culbertson [1997], *The International Journal of the Economics of Business* devoted an entire special issue, November 1997 (Vol. 4, No. 3) to a Symposium on the US Brand Name Prescription Drug Antitrust Litigation, with Harold E. Frech III as guest editor. One of the current authors (ERB) was involved in that litigation on behalf of the defendant brand drug manufacturers.

<sup>92</sup> With fixed health ministry budgets, demand price elasticities would equal -1. It is generally believed that demand for health care is price inelastic; note that with a standard monopoly pricing framework with linear demand curves and constant marginal cost, the monopolist prices in the elastic portion of the market demand curve, with markup  $(P - MC)/P = -1/E_d$ , where  $P$ ,  $MC$  and  $E_d$ , are price, marginal cost and elasticity of demand, respectively. One plausible way in which to incorporate inelastic demand and negative markups is to permit time dependence in demand, such as long term maintenance treatment of medicines, or in the extreme addiction. As pointed out by Showalter [1999], recognizing that future demand for a product can be much larger than current period demand, the profit maximizing monopolist may price in the inelastic portion of the current period demand curve, with negative markup, since doing so will entice the consumer to begin consuming a life-long maintenance medicine in the current time period.

<sup>93</sup> We do not consider a perfectly competitive market for branded drugs, because perfect competition is in general inconsistent with differentiated products. While perfect competition might be a useful approximation to generic drug markets (see our earlier discussion), for brands this is clearly not the relevant microeconomic framework.

<sup>94</sup> <http://www.medpac.gov/chapters/Jun09DataBookSec11.pdf>

<sup>95</sup> The policies often had an initial deductible such as \$50 or \$100. If the consumer expects to exceed such a deductible with certainty, it creates only a modest income effect. If not, demand depends on the expected marginal price at the end of the accounting period. See Keeler, Newhouse and Phelps [1977].

<sup>96</sup> The dollar expenditure at which 5 percent coinsurance takes effect changes each year, but in 2009 was \$6,356.

<sup>97</sup> See, for example, Danzon and Pauly [2001, 2002].

<sup>98</sup> Aitken, Berndt and Cutler [2008].

<sup>99</sup> Many chronic drugs can also be purchased from the insurer (pharmacy benefit manager) by mail order. In this case a common arrangement is to price a three month supply for a copayment less than three times the 30-day copay. This has the effect of passing on to the consumer some of the savings of the pharmacists' dispensing fee.

<sup>100</sup> Not surprisingly, estimated price elasticities of demand for these specialty drugs are very small; for one set of estimates, see Goldman, Joyce, Lawless et al. [2006].

<sup>101</sup> Sometimes the coinsurance applies only after the consumer has spent a certain amount out-of-pocket. In this case the above coinsurance analysis does not apply unless the benefit is valued sufficiently highly by the insured so that s/he is willing to spend the amount needed to arrive in to the coinsurance region. There is also an income effect on demand from spending this amount, which may mitigate the manufacturer's ability to increase the pre-insurance price.

<sup>102</sup> The six classes are antidepressants, antipsychotics, anticonvulsants, immunosuppressants, antiretroviral and antineoplastic.

<sup>103</sup> [http://www.nu-retail.com/The\\_Express\\_Scripts\\_Wellpoint\\_PBM\\_Deal.pdf](http://www.nu-retail.com/The_Express_Scripts_Wellpoint_PBM_Deal.pdf). The Wellpoint – Express Scripts merger referred to in this document was permitted by U.S. antitrust authorities and has been consummated.

<sup>104</sup> <http://www.cms.gov/NationalHealthExpendData/downloads/tables.pdf>, Table 11.

<sup>105</sup> See Scott Morton [1997] and Duggan and Scott Morton [2006].

<sup>106</sup> While patent protection and monopoly power result in deadweight loss relative to perfect competition, Garber, Jones and Romer [2006] report simulations that when moral hazard from insurance is taken into account, quantity demanded approaches the efficient perfectly competitive outcome, but the resulting prices are much higher.

- <sup>107</sup> See, for example, Rosenthal, Berndt, Donohue et al. [2002].
- <sup>108</sup> Berndt [2001,2002] considers marketing issues in greater detail.
- <sup>109</sup> For a recent example involving Pfizer’s \$2.3 billion settlement with the U.S. Department of Justice, see Harris [2009].
- <sup>110</sup> Chernew, Rosen and Fendrick [2007].
- <sup>111</sup> For further discussion, see Gruber and Koszegi [2001].
- <sup>112</sup> For further work along these lines, see Chernew, Rosen and Fendrick [2007], Ellis and Manning [2007], Goldman and Philipson [2007] and Newhouse and Sinaiko [2008].
- <sup>113</sup> Pharmacy Benefit Management Institute [2009], p. 8. A given employer might have multiple responses.
- <sup>114</sup> Pharmacy Benefit Management Institute [2009], p. 8, 14.
- <sup>115</sup> Pharmacy Benefit Management Institute [2009], p. 8.
- <sup>116</sup> Pharmacy Benefit Management Institute [2009], p. 18.
- <sup>117</sup> In addition to references cited earlier, see Congressional Budget Office [2004, 2007]. Pharmacy Benefit Management Institute [2009], p. 23, reports that for retail and mail order generics, the average discount off AWP in 2009 was 45.8% and 57.3%; MAC pricing is used by 70.6% of employers for retail generic prescriptions, and by 45.5% of employers for mail order prescriptions.
- <sup>118</sup> See Aitken, Berndt and Cutler [2008] for further discussion.
- <sup>119</sup> Evidence suggests that variation among states in the extent to which patients must consent to substitute generic for brand has a substantial impact on Medicaid generic prescribing rates; see Shrank, Choudhry, Agnew-Blais et al. [2010].
- <sup>120</sup> Berndt [2005] discusses this phenomenon in greater detail, noting the important role of therapeutic class effects.
- <sup>121</sup> CVS Caremark [2009], p. 14.
- <sup>122</sup> See, for example, CVS Caremark [2009], p. 15. Incidentally, for branded specialty drugs, the Pharmacy Benefit Management Institute [2009, p. 23] reports that the mean discount off AWP for specialty drugs in 2009 was 17.9%, slightly greater than the 16.4% for retail brand.
- <sup>123</sup> Bach [2009].
- <sup>124</sup> Taken from Bach [2009], p. 626.
- <sup>125</sup> Aitken, Berndt and Cutler [2008], based on data from IMS Health.
- <sup>126</sup> For further discussion, see Duggan and Scott Morton [2010].
- <sup>127</sup> Frank and Newhouse [2007, 2008].
- <sup>128</sup> Frank and Newhouse [2008], p. 37.
- <sup>129</sup> Frank and Newhouse [2008], p. 38.
- <sup>130</sup> Berndt and Frank [2007] report more rapid price increases for elderly intensively used drugs in anticipation of the January 2006 implementation of Part D than after based on Producer Price Index data by therapeutic class, although at the aggregate class level the results were less evident.
- <sup>131</sup> Berndt, Cockburn, Cocks et al. [1998].
- <sup>132</sup> As quoted in Drug Channels [2009a], p. 2.
- <sup>133</sup> The law requires that 70% of rural beneficiaries must live within fifteen miles of a pharmacy.
- <sup>134</sup> Drug Channels [2007a], p. 1. Also see Wal-Mart [2010].
- <sup>135</sup> Agwunobi and London [2009].
- <sup>136</sup> In instances in which the price of a generic drug is less than the copayment, the consumer typically pays the lower price.
- <sup>137</sup> Drug Channels [2007a], p. 1.
- <sup>138</sup> Drug Channels [2008b], p. 1.
- <sup>139</sup> Using data published in June 2007 by the Office of the Inspector General (“OIG”) at the Department of Health and Human Services on pharmacy’s actual average acquisition costs, for the six generic drugs on both the OIG report and available at WalMart, one observer computed a weighted average gross margin for WalMart of 24%, using the \$4 per prescription price. To the extent WalMart is able to purchase at less than the actual average national price, this gross margin is understated. See Drug Channels [2007b].
- <sup>140</sup> Drug Channels [2008c].
- <sup>141</sup> Drug Channels [2008d, 2008e].
- <sup>142</sup> See, for example, Abelson [2010].
- <sup>143</sup> Drug Channels [2009b].
- <sup>144</sup> Drug Channels [2008f].

<sup>145</sup> See, for example, Scott [2006].

<sup>146</sup> This is known as the Averch-Johnson effect after Averch-Johnson [1962], and more colloquially as “rate base padding.”

<sup>147</sup> For a discussion of issues underlying “optimal transparency”, and the pros and cons of transparent pricing in the context of pharmaceuticals, see Congressional Budget Office [2008] and Berndt [2005], particularly Section IV.